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ABSTRACT 
In the present review, associations between traditional vascular risk factors (VRFs) and 
carotid intima-medial thickness progression (C-IMTp) as well as the effects of therapies for 
VRFs control on C-IMTp were appraised to infer causality between each VRF and C-IMTp. 
Cohort studies indicate that smoking, binge drinking, fatness, diabetes, hypertension and 
hypercholesterolemia are associated with accelerated C-IMTp. An exception is physical 
activity, with mixed data. Interventions for the control of obesity, diabetes, hypertension 
and hypercholesterolemia decelerate C-IMTp. Conversely, scarce information is available 
regarding the effect of smoking cessation, stop of excessive alcohol intake and 
management of the metabolic syndrome. Altogether, these data support a causative role 
of several traditional VRFs on C-IMTp. Shortcomings in study design and/or 
ultrasonographic protocols may account for most negative studies, which underlines the 
importance of a careful consideration of methodological aspects in investigations using C-
IMTp as the outcome. 
 
Key words: atherosclerosis, risk factors, carotid intima-medial thickness, atherosclerosis 
progression, ultrasonography, causality. 
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1. INTRODUCTION 
Changes in subclinical atherosclerosis over time has been utilized to investigate which 
environmental or endogenous conditions accelerate atherosclerosis progression and 
which life-style or pharmacological interventions retard, or even halt, this process. 
Progression of subclinical atherosclerosis may be assessed by measuring changes of the 
intima-medial thickness of carotid arteries (carotid intima-medial thickness progression or 
C-IMTp) using non-invasive ultrasonographic techniques. Numerous studies have been 
published reporting associations between exposure to traditional cardiovascular risk 
factors (VRFs), their control and C-IMTp. The results of these studies are rather 
heterogeneous, possible due to differences in study population, sample size, length of 
follow-up, methodology of C-IMT measurement and statistical analyses.  
In the present narrative review, we examine critically the literature on this topic to provide 
support or to question inferences of causal VRFs – C-IMTp relationships.  
 
2. MATERIALS AND METHODS 
PubMed was searched for original articles with full text available published until June 
2019, by combining the following terms: 1) “carotid IMT OR carotid intima* media* thick*” 
AND 2) “progression OR chang*”, limiting the search to human studies written in English. 
Given the vast number of published studies that are either small, short-term and/or without 
proper methodologies, this review was restricted to studies that fullfil the following minimal 
prespecified inclusion criteria:  
1. time between baseline and final C-IMT assessment ≥ 12 months 
2. proper statistical power (α = 0.05, β > 80%) 
3. reported assessment of reproducibility of C-IMT measurements 
4. statistical analysis with mandatory adjustment for age and gender and optional 
adjustment for a variable series of other potential confounders. 
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Figure 1 shows the flowchart of study selection, as well as the number of studies excluded 
and the reasons for exclusion. Selected studies included observational population-based 
studies and clinical trials. In the latter, data from the placebo groups were considered, 
whenever available, to describe relationships between putative risk factors and C-IMTp, 
whereas data from the actively treated group/s were considered to describe the effect of 
the intervention/s on C-IMTp. Each title and/or abstract identified by the search strategy 
was independently reviewed by two investigators (BF, PW), who determined the potential 
eligibility of the study. Full texts of potentially suitable articles were obtained and further 
screened for inclusion. Controversies were discussed and solved with a third investigator 
(DB). Selected studies were tabulated according to main distinct categories of traditional 
risk factors reported to influence C-IMTp.  
Given the methodological heterogeneity of ultrasonographic protocols, detailed data were 
obtained regarding the carotid segment/s, carotid side (left and/or right) and arterial 
interface (far-wall and/or near-wall) considered in each study. In addition, since risk factors 
and their control could affect IMT and atherosclerotic plaques differently, it was specified 
whether IMT measurements incorporated plaques or not. Collected data was scrutinized 
by three investigators (MA, DS, LV) for potential influences of these methodological 
features on study results.  
Due to the heterogeneity of study types (observational or interventional), type of population 
(healty subjects or other), ultrasonographic protocols, follow-up length, etc., a 
metanalytical approach was deemed unsuitable and the results are presented in a 
narrative style as reported in each study.  
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3. RESULTS 
Unmodifiable vascular risk factors and C-IMTp 
Aging, male gender and familial history of premature cardiovascular events are among the 
most powerful VRFs and each of them has been consistently associated with accelerated 
C-IMTp [1-9]. These risk conditions are not modifiable and do not represent targets of 
therapy. Conversely, we focus on modifiable VRFs. Though several of these conditions 
are very commonly interrelated (e.g. obesity with hypertension or diabetes, physical 
activity with food intake and metabolic syndrome, etc.), they will be considered separately, 
as far as possible, in an attempt to appreciate the relationship between each specific 
modifiable VRF and C-IMTp. 
 
Life style  
Cigarette smoking, physical inactivity, excessive alcohol intake and unhealthy diet are the 
most consolidated life-style associated VRFs. The following paragraphs describe the 
relationship between these conditions and C-IMTp as well as the effect of lifestyle 
modifications. 
 
Cigarette smoking and C-IMTp 
The relationship between smoking status and C-IMTp was investigated in general 
populations and specific patients cohorts (Table 1; supplementary material). In the KIHD 
cohort study, a population-based sample of middle-aged Finnish men, smokers had a 2.1-
fold (P=0.007) age-adjusted C-IMTp compared with nonsmokers during 2-years follow-up 
[10]. Significant effects of cigarette smoking were observed also in the ARIC, a population-
based cohort study of middle-aged American adults among which, in a 3-years follow-up, 
current smokers and former smokers showed a 50% and 25% higher C-IMTp, 
respectively, than never smokers [11]. 
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In a small group of patients with metabolic syndrome (n=301), four groups were identified 
according to smoking status at entry and at 12 months: never smokers, past smokers, 
quitters, and persistent smokers. After 12 months of follow-up even a C-IMT regression 
was observed in never smokers, past smokers and quitters (by -2.78%, -0.33%, and -
1.16%, respectively), whereas persistent smokers showed a progression of 33.3% from 
baseline [12]. Current or even past smoking emerged by multivariate analyses as 
independent predictors of C-IMTp in many other population-based cohort studies 
[4,7,8,13-19], as well as in patients with hypercholesterolemia [20], type 1 diabetes 
(T1DM) [21], or cardiovascular disease (CVD) [22]. Moreover, the impact of smoking on C-
IMTp appeared to be greater in subjects affected by diabetes and hypertension, as shown 
in the ARIC study [11]. 
The higher C-IMTp observed in former smokers than in never smokers suggests that 
previous exposure to cigarette smoke may engender a kind of “memory” effect [4,11]. Yet, 
no data about the time elapsed since smoking cessation is provided in these studies and 
therefore, how long this putative memory of smoke on C-IMTp could persist is currently 
unknown. 
Even passive smoking was recognized as a cardiovascular risk factor for CVD [23]. In the 
ARIC Study, subjects who were in close contact with smokers for more than one hour per 
week in the past year had, in a 3-years follow-up, a 20% higher C-IMTp than those not 
exposed [11]. All together, these observational data suggest that both active and passive 
smoking are risk factors for C-IMTp.  
 
Smoking cessation and C-IMTp 
Curiously, only one study investigated the effect of active intervention on smoking 
cessation on C-IMTp and, paradoxically, there was a greater increase of C-IMT among 
subjects who were continuously abstinent compared to those who smoked continuously (p 
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=0.020) in a 3-years follow-up [24] (Table 1; supplementary material). A possible 
explanation to this counterintuitive finding is that the significantly higher weight gain in 
abstinents (by two BMI points, >10-fold vs continuers) could have offset the favorable 
effect of smoke quitting. It is worth noting that in this study IMT was measured only in the 
distal 1 cm of each common carotid artery, a segment hardly affected by atherosclerosis 
(see below paragraph on “controversies”). Indeed, the authors openly recognize that the 
effect of smoking cessation of C-IMTp in the internal carotid or bulb may have been 
different to that observed in the common carotid artery. 
 
Alcohol consumption and C-IMTp 
The association between binge drinking (heavy acute intake of alcoholic beverages) and 
C-IMTp was investigated in a population-based sample of middle-aged Finnish men from 
the KIHD study (Table 2; supplementary material) [25,26]. After a 4-years follow-up, heavy 
binge drinkers (≥480 ml of vodka) had a significantly higher C-IMTp than less heavy ones 
(≤240 ml of vodka) [25]. A similar but not significant trend was observed with the beer-
drinking pattern [25]. These results were corroborated after 11-years follow-up [26]. We did 
not find studies about the association between excessive chronic daily alcohol 
consumption and C-IMTp.  
 
Cessation of excessive alcohol consumption and C-IMTp 
We did not find eligible studies on the effect of cessation of either binge or daily excessive 
alcohol consumption on C-IMTp. 
 
Dietary style and C-IMTp 
A few observational studies investigated the association between spontaneous dietary 
habits and C-IMTp (Table 3; supplementary material). In the IRAS, a multi-center 
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observational study conducted in a multi-ethnic cohort of middle-aged adults, the impact of 
various food patterns on C-IMTp was investigated in a subgroup of non-diabetic subjects 
followed for 5 years [27]. The results showed that a high intake of low-fiber bread and 
cereal, red and processed meat, cottage cheese, tomato foods, regular soft drinks and 
sweetened beverages, along with a low intake of wine, rice, pasta and poultry is 
associated with an accelerated C-IMTp. In another publication of the same study, an 
inverse but marginally significant association between whole grain intake and C-IMTp was 
observed [28]. 
In the Los Angeles Atherosclerosis Study [29], a prospective study in middle-aged adults 
without CVD followed for 2 years, the intake of viscous fiber and pectin was inversely 
associated with C-IMTp. 
Plasma carotenoid levels, which may reflect carotenoid intake, were also inversely 
associated with C-IMTp [30-32].  
A positive association was found between dietary sodium intake and C-IMTp during 5.3 
years of follow-up in Korean adults aged 40 years and older.[33]  
Thus, different food components have been associated with the rate of C-IMTp in 
observational studies. However, observations may be affected by confounding factors 
such as deleterious or protective habits that cluster with a certain self-chosen food intake.  
 
Dietary changes and C-IMTp 
Interventional studies investigating the effect of specific foods or dietary patterns on C-
IMTp are summarized in Table 3; supplementary material. A low fat “prudent-like” phase A 
diet or the Mediterranean Diet, the most widely recommended “heart-friendly” dietary 
patterns, have been both associated with positive effects on C-IMTp. In fact, in elderly men 
with long-standing hyperlipidaemia, prescription of a phase A diet (≤30% of energy from 
fat, saturated fat <1/3 of total fat, cholesterol <300 mg/day, <15% of energy from protein, 
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≥55% of energy from carbohydrates and not more than 2-3% of energy from alcohol) was 
associated with a significant reduction in C-IMTp (p=0.047) as compared with a control 
group without dietary advice [34]. Besides, in a post-hoc analysis of the PREDIMED Study, 
the effects on C-IMTp of a Mediterranean Diet enriched with either nuts or virgin olive oil, 
as compared with a low-fat control diet, were evaluated in 187 high-risk asymptomatic 
Spanish adults. After 1-year, no significant between-group difference in C-IMTp was 
observed. However, in a subgroup of subjects with elevated baseline C-IMT (>0.9 mm), 
both types of Mediterranean Diets, but not the control diet, not only reduced C-IMTp but 
even induced C-IMT regression [35]. Moreover, in a 2.4-years follow-up of another 
PREDIMED subcohort of 175 high-risk asymptomatic adults from Barcelona (Spain), a 
Mediterranean Diet supplemented with nuts but not with virgin olive oil was associated with 
a delayed C-IMTp, whereas a significant C-IMT progression was observed in participants 
allocated to the control diet group [36]. Whether these positive effects depend on specific 
nutrients of the Mediterranean Diet or to the whole Mediterranean style is unknown. 
In people with diabetes, increasing the intake of fruit (+1 serving; 150 g/day), vegetables 
(+2 servings; 150 g/day), and dairy products (+1 serving; 200-250 g/day) slowed the 12-
months C-IMTp compared with a control group on usual diet [37]. 
Positive results were also obtained with n-3 fatty acids supplementation. In a randomized 
open study in Japanese type 2 diabetics, C-IMT of the group treated with 
eicosapentaenoic acid (EPA, 1800 mg/day) for about 2 years showed a significant 
regression compared with the untreated control group [38].  
In hypertensive patients, the level of adherence to a fish-rich dietary intervention, 
assessed through changes in the PUFA/SFA ratio, was inversely related to C-IMTp [39]. 
Negative results were obtained with isoflavone soy supplementation in postmenopausal 
women [40]. However, a reduced C-IMTp was observed in women who were in 
menopause since less than 5 years, suggesting that the beneficial effect of isoflavone soy 
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supplementation could be achieved only if the treatment is started close to the beginning 
of menopause. 
The vitamin most frequently tested for a putative anti-atherosclerotic effect was vitamin E. 
Contrarily to the positive results of early observational studies [41], most randomized trials 
aimed at evaluating the effect of vitamin E on C-IMTp have shown no effect [42-44]. 
Curiously, whereas vitamin C alone failed to reduce C-IMTp in randomized studies, a 
positive effect was observed with a combination of vitamins E and C [45,46].  
Overall, the evidence supports that the Mediterranean diet style may halt C-IMTp whereas 
the strength of available evidence for a role of any specific food, nutrient or micronutrient 
supplement is rather weak. 
 
Physical activity and C-IMTp 
A few observational studies investigated the relationship between levels of physical activity 
and C-IMTp (Table 4; supplementary material). In the Los Angeles Atherosclerosis Study, 
physical activity during leisure time in 500 healthy adults was inversely associated with the 
3-years C-IMTp [47]. A paradoxical positive association between workplace physical 
activity and C-IMTp was observed in this study, in agreement with results of another 
prospective study in Finnish men followed for 11 years [48]. This paradox might be 
explained by confounding factors not considered in the multivariate analyses or, 
alternatively, by opposing effects on C-IMTp of different neuro-hormonal changes during 
physical activity performed in leisure time (usually pleasant) versus working time (often 
stressful). In another study carried out in a healthy European population, the average 
intensity of daily physical activity, objectively measured using an accelerometer, was 
unrelated to the 3-years C-IMTp [49]. However, C-IMTp was significantly lower in subjects 
with vigorous activity than in those with light-to-moderate activity. Thus, results of 
observational studies on physical activity and C-IMTp are not consistent, but suggest that 
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a deceleration of C-IMTp, if any, might be related to how vigorous the physical activity is 
and in which context it is carried out.  
 
Physical activity interventions and C-IMTp 
In patients with type 2 diabetes, a 1-year intervention based on 3 weekly exercise sessions 
of either “high-intensity interval training” or “moderate continuous training” (both on top of 
resistance training) significantly reduced C-IMTp as compared with controls, who only 
received standard counseling and information regarding general physical activity [50]. 
In contrast, in a group of adolescents, no differences in C-IMTp were observed between a 
sport practice group (≥ 300 min/week of organized sports) and a control group (non-sport 
practice) during 1-year of follow-up [51]. A possible explanation to this discrepancy 
between results is that C-IMTp in healthy adolescents may be too slow, as compared with 
diabetic adults, to detect treatment effects in a 1-year period of intervention.  
 
Combined dietary and physical activity interventions and C-IMTp  
Table 5 (supplementary material) shows data on the effect of diet plus physical activity on 
C-IMTp. In perimenopausal and postmenopausal women, a 4-years lifestyle intervention 
(reduced calories, total and saturated fat and cholesterol dietary intake and increased 
leisure time physical activity) halved C-IMTp vs a control group (0.004 mm/y vs 0.008 
mm/y, P=0.02) [52]. Moreover, not merely a reduced C-IMT progression but even a 
regression was observed in Japanese hypercholesterolemic patients [53] and in obese 
adolescents [54,55] subjected to a dietary and physical activity intervention for 2-years and 
1-year, respectively. However, in another controlled study, a similar lifestyle intervention 
for 4 years in postmenopausal women did not affect C-IMTp [56]. Similarly, no effects on 
C-IMTp of intensive combined lifestyle changes were reported in sedentary hypertensive 
and hypercholesterolemic men in the HYRIM trial [57]. Altogether, these results are rather 
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contradictory and therefore, a favorable effect of diet plus physical activity on C-IMTp may 
be not generalizable but detectable only in distinct groups subjected to specific 
interventions.  
 
Obesity and C-IMTp 
The association between obesity and C-IMTp was investigated in observational studies, 
but using different measures of body fatness and in dissimilar populations (Table 6; 
supplementary material). Altogether, most studies support the concept that obesity has a 
deleterious effect on C-IMTp. Indeed, with the exception of the ARIC study [58], BMI was 
an independent predictor of C-IMTp in a sample of middle-aged employees [59] and in 
current smokers [24]. In addition, waist circumference was directly associated with C-IMTp 
in a population based cohort [60] and waist-to-hip ratio was associated with accelerated C-
IMTp both in a population based cohort [61] and in patients with coronary artery disease 
(CAD) [22]. Thus, though available data are not fully consistent, body fat seems to 
associate with accelerated C-IMTp at least in some population or patients’ categories. 
 
Weight loss in obesity and C-IMTp 
Either weight loss obtained through medical nutritional interventions [62-64] or bariatric 
surgery [65-67] has been associated with a reduced C-IMTp in several studies (Table 6; 
supplementary material). Of particular interest is the study of Buscemi et al.[62] which 
shows a significant correlation between changes in body weight and changes in C-IMT. 
Conversely, treatment of obese patients with rimonabant for 30 months, though effective in 
reducing body weight compared to placebo, did not influence C-IMTp [68]. Therefore, it is 
possible that weight loss induced by drugs may not exert the favourable effect on C-IMTp 
obtained in obese patients with reduced energy intake or increased energy expenditure.  
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Other studies investigated the effect of weight loss on C-IMTp in children [63,64]. In obese 
children with non-alcoholic fatty liver disease, C-IMT did not change significantly after a 1-
year intervention program of hypocaloric diet and physical exercise [64]. Though the 
absence of progression might be interpreted as a positive outcome, the lack of a control 
group in this study impedes to seize the true impact of the intervention. However, the C-
IMT regression observed in overweight children subjected to weight-reducing life-style 
changes in another study [63] suggests a favorable effect of weight loss on C-IMTp even 
in children.  
 
Metabolic syndrome and C-IMTp  
The Metabolic Syndrome (MetS) is a prevalent condition characterized by central obesity, 
hypertension, hypertriglyceridemia, low HDL-C levels and insulin resistance. 
In the Young Finns Study cohort, patients with MetS at baseline had an accelerated C-
IMTp during 6-years of follow-up compared with those without [60] (Table 7; 
supplementary material). Similar findings were reported in middle-aged Japanese women 
[69], in middle-aged men free of diabetes and CVD [70], in an elderly population [71] and 
in apparently healthy adults [72] followed for variable periods. In the population-based 
Tromsø Study, MetS at baseline was associated with C-IMTp during 13-years follow-up in 
subjects below 50 years of age at baseline [73]. Only in the ELSA study, the presence of 
MetS was not associated with C-IMTp: however, this was a randomized trial conducted in 
hypertensive patients with higher baseline C-IMT. In this particular population, the strong 
effect of hypertension and of hypertensive treatment could have masked the effect of MetS 
[74]. Statistical models, applied to data from the Los Angeles Atherosclerosis Study, 
suggest that the atherogenicity of MetS is mediated by its components, with possible 
gender-based differences; for example, triglycerides were significantly associated with C-
IMTp only in women [75].  
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In at least two [70,72] of these studies [69-74], a change from a normal metabolic status at 
baseline to the presence of MetS at follow-up (or the presence of MetS at both visits) was 
associated with an increased C-IMTp, compared to patients with MetS at baseline but not 
at follow-up, in whom a reduced C-IMTp was observed [69,76]. 
 
Treatment of the metabolic syndrome and C-IMTp 
The lack of interventional studies in MetS with assessment of C-IMTp impedes to 
strengthen the notion of MetS as a risk factor for C-IMTp. 
 
Glucose derangement and C-IMTp  
The influence of abnormalities in glucose metabolism on C-IMTp has been investigated in 
several observational studies (Table 8; supplementary material). Results of the IRAS study 
[14] suggest that C-IMTp relates to the severity of the glucose metabolism derangement. 
In fact, in a 5-years follow-up, C-IMTp was the lowest in subjects with normal glucose 
tolerance, greater in patients with impaired glucose tolerance, and the greatest in those 
with either known or newly diagnosed T2DM. These results are in line with other studies 
showing that baseline T2DM [4,9,16,17,77-79] and onset of T2DM during follow-up [17] 
are associated with an increased C-IMTp. Studies performed solely in patients with T2DM 
[3,80] show an annual C-IMTp significantly higher than that reported in general 
populations. Results of studies that used biochemical markers of glucose derangement 
coincide with those that compared discrete clinical diagnostic categories. In fact, fasting 
glucose predicted C-IMTp in population studies [13,19,81]. Similarly, HbA1c levels were 
directly associated with C-IMTp in three [3,82,83] out of four studies carried out in patients 
with T2DM [3,82-84]. Significant associations with C-IMTp were also reported for glycated 
albumin (GA) [83], HbA1c/GA ratio [83] and 2-h post-challenge glucose [82]. HOMA index 
was associated with C-IMTp in a prospective cohort study [13].  
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In summary, most of these studies indicate that pre-diabetes and overt T2DM are 
associated with an accelerated C-IMTp.  
For obvious reasons (immediate need of insulin treatment), no observational data are 
available on the natural history of C-IMTp in T1DM. As well, data are lacking regarding C-
IMTp in less prevalent disorders of glucose metabolism, such as gestational or secondary 
diabetes.  
 
Diabetes control and C-IMTp 
Hypoglycaemic drug therapies (acarbose [85], voglibose [86], nateglinide [87], alogliptin 
[88], sitagliptin [89]), tested versus placebo or an untreated group, retarded C-IMTp, 
whereas gliclazide [90], repaglinide [91] or glibenclamide combined with metformin [90] 
outperformed in comparison with glibenclamide monotherapy (Table 8; supplementary 
material). One study evaluated the effect of troglitazone on C-IMTp in patients with T2DM 
before the drug was withdrawn from the market due to liver toxicity. Compared with 
placebo, troglitazone treatment did not reduce C-IMTp in insulin-requiring type 2 diabetics 
[92]. Similarly, rosiglitazone did not affect C-IMTp in patients with T2DM [93,94] or pre-
diabetes [95]. Conversely, pioglitazone (the only thiazolidinedione still in commerce), 
reduced C-IMTp in patients with impaired glucose tolerance (versus placebo) [96] and in 
patients with T2DM, as compared with either glimepiride [97] or with non-thiazolidinedione 
oral anti-diabetic drugs [98]. These data suggest that the anti-atherosclerotic effect of 
thiazolidinediones may be compound specific. Yet, studies by Xiang et al. showed that, in 
women with a history of gestational diabetes, both troglitazone [99] and pioglitazone [100] 
slowed C-IMTp, possibly indicating a singular efficacy of thiazolidinediones in this specific 
patient population.  
In the ORIGIN-GRACE study [101], patients with CVD and/or traditional VRFs plus a) 
impaired fasting glucose, b) impaired glucose tolerance, or c) early T2DM received insulin 
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glargine or standard glycemic care. The effects of insulin glargine and standard care did 
not differ significantly in terms of C-IMTp. 
The result of this study suggest that insulin treatment in patients with T2DM, though often 
needed to control hyperglycemia, may not favorably impact C-IMTp. 
The case seems to be different in hypoinsulinemic conditions. The effect of intensive 
glycemic control on C-IMTp in patients with T1DM was assessed in the EDIC study [21], 
which was a long-term follow-up of the DCCT study [102]. In the DCCT study, patients had 
been treated for 6.5 years with either conventional therapy (one or two daily injections of 
insulin, without adjustment of insulin dosage) or with intensive therapy (insulin three or 
more times daily, with dosage adjusted according to the results of glucose self-monitoring). 
During the subsequent EDIC study, all patients received intensive therapy and were 
reevaluated at one, six and twelve years after EDIC start. In the EDIC study, [21] C-IMTp 
was lower in patients that, in the original DCCT study, had been treated intensively than in 
those that had been treated conventionally [102]. This suggests that early initiation of 
intensive insulin treatment in T1DM may retard atherosclerosis progression. 
In summary, in T2DM, drugs used to control glucose metabolism affect C-IMTp differently, 
and some of them retard it significantly. Moreover, precocious intensive insulin therapy 
slowed C-IMTp in T1DM. Overall, these results support a pathogenic role of abnormalities 
in glucose metabolism on C-IMTp.  
 
Hypertension and C-IMTp 
Diagnosis of hypertension [4,8,9,14-16] and blood pressure levels [4,7,13,19,75,77,103-
106] were both directly associated with C-IMTp, with one exception [81] (Table 9; 
supplementary material). Moreover, several blood pressure variables associated with C-
IMTp differently [17,107-110]. Specifically, in the KIHD study, baseline systolic blood 
pressure (SBP) but not diastolic blood pressure (DBP) had a strong and graded positive 
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relationship with C-IMTp [108]. Another study suggests that C-IMTp already starts to 
accelerate at SBP levels of about 120 mmHg [108]. Finally, pulse pressure [17,107,108] 
and blood pressure changes [109,110] were also associated with increased C-IMTp.  
 
Control of hypertension and C-IMTp 
In population-based cohorts, baseline use of anti-hypertensive medication was associated 
with reduced C-IMTp during follow-up [8,111] (Table 9; supplementary material).  
The Campania Salute Network assessed whether different targets of SBP (tight control: 
SBP<130 mmHg or usual control: SBP 130-140 mmHg) achieved during follow-up are 
associated with different C-IMTp in a group of 4,148 treated hypertensive patients. After a 
median follow-up of 74 months, C-IMTp was similar in both groups without significant 
difference related to SBP target. However, it should be stressed that participants had a 
long-lasting history of hypertension, were under antihypertensive treatment and, in most 
cases, were already in good blood pressure control. Thus, it is possible that in many cases 
the maximal effect achievable with antihypertensive treatment had already been obtained 
in many patients, thus reducing the chance to detect substantial changes in C-IMTp [112]. 
Many randomized clinical trials evaluated the effect of anti-hypertensive therapy on C-
IMTp. Favorable effects were obtained with either diuretics [113], β-blockers [114-117], 
ACE inhibitors [44,118,119], angiotensin II receptor antagonists [116], calcium channel 
blockers [113-115,118,120] or α1 receptor -selective blockers [121]. Only a few studies 
with ACE inhibitors failed to detect significant effects. [95,122,123] 
A study suggests that reducing SBP to less than 115 mmHg results in a greater reduction 
of C-IMTp compared to less intensive treatment [124]. This study showed that, in diabetic 
patients, an aggressive therapy aimed at decreasing SBP to values ≤115 mmHg and LDL-
C to values ≤70 mg/dl halted C-IMTp, whereas C-IMT progressed in less intensively 
treated patients. However, it is not discernible whether the beneficial effect is related to the 
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intensity of the anti-hypertensive treatment or, rather, to the combined lipid and blood 
pressure intensive control. The consistent results of both observational studies and blood 
pressure lowering interventions (with the exception of some ACE inhibitors), strongly 
support a pathogenic role of high blood pressure on C-IMTp. 
 
Dyslipidemia and C-IMTp 
Total cholesterol and LDL-C levels were directly associated with C-IMTp in population 
based cohorts [4,7,10,15,60,125-128], in healthy subjects [18,129-131] and in patients with 
diabetes [82] (Table 10; supplementary material). 
Similar direct associations with C-IMTp were reported for triglycerides [126,132], whereas 
HDL-C levels associated inversely with C-IMTp in population based cohorts 
[13,17,111,126,133], in patients with VRFs [82,130,134,135] or CAD [22]. 
Studies performed in different patient populations investigated also associations of C-IMTp 
with lipid ratios, lipoprotein species, apolipoproteins and modified lipoproteins. Significant 
direct associations were reported for TC/HDL-C [9,132], TG/HDL-C [132], ApoB/HDL-C 
[132], VLDL-C [135], VLDL1+2-C [135], ApoB levels [126] or ApoB/ApoA-I ratio [136]. 
Levels of HDL2-C and HDL3-C associated inversely with C-IMTp [135].  
The association of C-IMTp with lipoprotein(a) levels [137,138] was not fully consistent. 
Indeed, levels of lipoprotein(a) were associated with C-IMTp in one high-risk condition (i.e. 
T2DM) [137] but not in another (heterozygous familial hypercholesterolemia)[138]. 
 
Control of dyslipidemia and C-IMTp 
Many studies demonstrated a favorable effect of lipid management on C-IMTp (Table 10; 
supplementary material). In two observational cohort studies, baseline or long-term use of 
drugs affecting lipid metabolism was an independent predictor of reduced C-IMTp 
[111,139]. Moreover, a plethora of clinical trials with different statins consistently showed a 
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slower C-IMTp in patients actively treated with a statin versus placebo [20,57,140-150] or 
versus a less potent statin [151], with only few exceptions [152,153]. Indeed, treatment of 
different patient groups with lovastatin [140-143], pravastatin [20,144-146,153,154], 
rosuvastatin [147-149], fluvastatin [57,155], atorvastatin [150] or pitavastatin [156] was 
superior in decreasing C-IMTp than either placebo or a lower-dose of the same statin or a 
statin with less LDL-C lowering efficacy. An exception to these results was a study with 
pitavastatin and atorvastatin, in which the former produced a greater percent reduction in 
C-IMTp than the later, even if they were used at equipotent LDL-C lowering doses [151]. 
The effect of statins on C-IMTp was not evident in only one study in T2DM patients, where 
treatment with cerivastatin (substituted with simvastatin when cerivastatin was withdrawn) 
did not influence C-IMTp differently to placebo [152].  
Though the beneficial effects of statins on C-IMTp might be related, at least in part, to 
purported lipid-independent pleiotropic anti-atherogenic actions, as suggested by a post-
hoc analysys of a statin trial [157], LDL-C lowering non-statin drug interventions also 
reduce C-IMTp [158,159], supporting LDL-C exposure as a major player in C-IMTp. 
Contrarily, the addition of ezetimibe on top of a statin, though more effective in terms of 
LDL-C reduction, was not superior in reducing C-IMTp than a statin alone [160-162]. A 
relatively negligible incremental effect on C-IMTp of ezetimibe on top of an already 
intensive treatment with statins (a kind of saturation) may be a plausible explanation to 
these negative findings. In addition, the single trial which reported a counter-intuitive 
inverse correlation between LDL-C changes and C-IMTp was with ezetimibe [163]. 
Exceptional insight may be gained from the results of lipid-lowering trials performed in 
patients with familial hypercholesterolemia (FH), as these patients have long-life and 
extremely high LDL-C levels as the main or even single VRFs. 
An open study investigated the effect of simvastatin 80 mg on both carotid and femoral 
IMT progression in FH patients [164]. After a 2-years follow-up, IMT significantly 
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decreased in both districts. In the first controlled study with statins in FH, namely ASAP, 
patients with heterozygous FH were randomized to atorvastatin 80 mg/day or simvastatin 
40 mg/day [165]. After 2 years, IMT decreased in patients treated with atorvastatin, and 
increased in those treated with simvastatin. After completion of the ASAP study, patients 
were invited to continue a 2-year extension study with atorvastatin 80 mg/day [166]. 
Participants who received atorvastatin in both periods had a complete arrest of C-IMTp 
whereas those who shifted from simvastatin to atorvastatin had significant IMT regression. 
These results indicate that a high-dose/high-potent statin is required to halt atherosclerosis 
progression in patients with FH. 
In the ENHANCE study, patients with heterozigous FH were randomized to simvastatin 80 
mg with either placebo or ezetimibe 10 mg. In line with previous trials with ezetimibe in non 
FH hypercholesterolemic patients [160-162,167], addition of ezetimibe to the statin did not 
result in significant differences in C-IMTp despite a greater reduction in LDL-C levels [168]. 
Altogether, the negative results of trials in non-familial and familial hypercholesterolemic 
patients raise the possibility of a compound-specific inefficacy of ezetimibe on C-IMTp. 
Only one study evaluated the effect of statins on C-IMTp in children with FH [169]. In this 
trial, a trend towards C-IMT regression was observed in those treated with pravastatin (20 
to 40 mg/day) and a trend toward C-IMT progression was seen in the placebo group. The 
two trends differed significantly [169]. 
Altogether, most of the interventional studies with statins and other non-statin drugs 
(except ezetimibe) support a pathogenic role of LDL-C on C-IMTp.  
Though a favourable effect of LDL-apheresis, partial ileal bypass or other non-
pharmacological LDL-C lowering interventions on C-IMTp might have reinforced the role of 
LDL-C on C-IMTp, we did not find studies with these interventions that fulfill the minimal 
methodological requirements prespecified in this review. 
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Studies with experimental lipid-modifying compounds provide insight about the influence of 
distinct lipoprotein species on C-IMTp. In RADIANCE 1, patients with heterozygous FH 
were randomized to either atorvastatin monotherapy or atorvastatin combined with 
torcetrapib, an inhibitor of the cholesterol ester transfer protein (CETP) which potently 
increases HDL-C. After 2-years follow-up, mean IMT decreased in the atorvastatin plus 
placebo group whereas it paradoxically increased in the atorvastatin plus torcetrapib 
group, notwithstanding the CETP inhibitor increased HDL-C by more than 50% [170]. 
Similar results were obtained in the RADIANCE 2 study in patients with mixed dyslipidemia 
[171] or in a pooled analysis [106].  
It is possible that, in these studies, the increase in systolic blood pressure observed in 
patients treated with torcetrapib partially offset the potential benefit expected by lipid 
modification. Overall, proper interventional studies focused on HDL-C are lacking to 
corroborate the above described observational data about a protective role of HDL-C on 
C-IMTp. 
Anyway, at the time being, a causal role of HDL-C itself on vascular disease is strongly 
debated and interventions that increase HDL-C levels have not demonstrated convincing 
changes in cardiovascular health overall [172-174].  
 
4. THE UNRESOLVED CONTROVERSY ABOUT THE CLINICAL SIGNIFICANCE OF C-
IMT PROGRESSION 
The clinical relevance of C-IMTp fully relies on its ability to predict clinical outcomes. 
Although C-IMT changes are supposed to be an expression of changes in systemic 
atherosclerosis and, as a result, a marker of the risk of major clinical atherosclerotic 
events, some studies have confuted this intuitive relationship. These studies include two 
meta-regression analyses [175,176], in which average changes in C-IMT induced by active 
treatments (vs either placebo or a comparative drug) were correlated with the log-
23 
 
transformed odds ratio for the clinical outcomes considered in each trial, using random-
effects. Utilization of study group averages instead of individual data has been viewed as 
one among a series of possible factors that might explain the failure of these meta-
regression analyses in demonstrating the expected ability of C-IMTp to predict clinical 
outcomes [177]. However, disappointing negative results were also reported in more 
recent meta-analyses of cohort studies in general populations [178], in patients with T2DM 
[179] and in high risk individuals [180] that, instead, computed individual data. In these 
latter studies, however, the analyses were focused on the relationship between clinical 
events and changes in IMT of the common carotid artery, which is the carotid segment 
more reproducibly assessed through vascular ultrasound but also the one less affected by 
atherosclerosis. Thus, a critical issue to consider in this controversy is the 
ultrasonographic protocol used to measure C-IMTp. In fact, protocols used so far to 
quantify C-IMTp may not appropriately reflect the focal process of atherosclerosis that 
account for vascular events. This possibility is suggested by a post-hoc analyses of the 
IMPROVE Study [181]. This multinational cohort investigation was aimed to evaluate the 
association between C-IMTp within 15 months and the rate of subsequent vascular events 
in a European population of adult patients at high cardiovascular risk. The study, indeed, 
shows that the only C-IMTp variable associated with cardiovascular outcomes is the newly 
devised “Fastest-IMTmax-prog”, which is the greatest C-IMTp observed among the 
progression values of IMTmax of the entire carotid tree [181]. Yet, the Fastest-IMTmax-prog 
was not a prespecified computation of the study and, therefore, replication in other large 
prospective studies carried out in general populations and patient groups is warranted to 
corroborate these findings.  
 
5. SO, ARE TRADITIONAL RISK FACTORS CAUSATIVE OF ACCELERATED C-IMTp? 
24 
 
In this review, we found that the reported associations between exposure to traditional 
cardiovascular risk factors (VRFs), their therapeutic control and C-IMTp comply with 
several of the Bradford Hill's criteria of causality [182,183] as follows:  
a) temporality is implicit in the observational cohort studies and in the intervention studies 
herein reviewed; 
b) consistency is fairly good. Indeed, most of the established modifiable risk factors, 
including cigarette smoking, binge drinking, fatness (at least in some patient categories), 
hyperglycemia, hypertension, the metabolic syndrome and hypercholesterolemia, were 
associated with an accelerated C-IMTp. An exception was physical activity, as 
observational studies provided mixed results;  
c) a biological gradient was recognizable with some risk factors, as C-IMTp related to the 
severity of the glucose metabolism derangement and with the extent of smoking exposure;  
d) the plausibility is supported by the knowledge that traditional risk factors accelerate 
atherosclerosis development by a variety of biological mechanisms and the recognition 
that carotid IMT is a surrogate of subclinical atherosclerosis; 
e) experiment: life-style changes or pharmacologic interventions to control 
hypercholesterolemia, hypertension, obesity and diabetes decelerate carotid wall 
thickening consistently. 
Knowledge gaps still remain to draw conclusive inferences of causality between some risk 
conditions and C-IMTp. In particular, the available information on the effect of smoking 
cessation (one single negative study), alcohol abandonment and metabolic syndrome 
management is very limited or lacking. 
Worth noting, several studies included in this review (n=24 out of 161 studies) did not find 
associations between traditional risk factors and C-IMTp or favorable changes in C-IMTp 
with interventions that reduce the alluded risk factors. However, a detailed scrutiny of 
these studies allowed us to identify, in most cases, one or more explanations to these 
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negative results: a) the population was very young and had baseline IMT in the normal 
range [51,64]; b) the time of observation was relatively short (1 year) to detect significant 
associations or changes in the sample investigated [51,64,93,94,167] and/or c) IMTp was 
evaluated only in the distal 1 cm of the common carotid artery, a segment hardly affected 
by atherosclerosis [24,40,42,43,51,64,81,84,92,122,123]. Actually, negative studies 
without one or more of these features (3 observational[49,74,112] and 5 interventional 
[56,57,95,101,152]  were uncommon, which underline the importance of an attentive 
consideration of methodological aspects in the design of studies aimed to ascertain the 
clinical significance of C-IMTp. 
In conclusion, the fairly consistent cause-effect relationship between traditional VRFs and 
C-IMTp evidenced in the present review and the potential relevance for research and 
patient care of having a non-invasive tool to monitor athero-progression strengthen the 
need to gain further knowledge on methodological aspects of C-IMTp quantitation and on 
the clinical significance and practical usefulness of C-IMTp assessment. 
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LIST OF ABBREVIATIONS  
C-IMTp = carotid intima-medial thickness progression 
VRFs= cardiovascular risk factors 
C-IMT = carotid intima-medial thickness 
T1DM = type 1 diabetes mellitus 
CVD = cardiovascular disease 
EPA = eicosapentaenoic acid 
PUFA = poly-unsatured fatty acids 
SFA = saturated fatty acids 
T2DM = type 2 diabetes mellitus 
CAD = coronary artery disease  
MetS = Metabolic Syndrome 
GA = glycated albumin 
SBP =  systolic blood pressure 
DBP = diastolic blood pressure 
LDL = low density lipoprotein 
HDL = high density lipoprotein 
TC = total cholesterol 
TG = triglycerides 
VLDL = very high density lipoprotein 
FH = familial hypercholesterolemia 
KIHD = Kuopio Ischaemic Heart Disease 
ARIC = Atherosclerosis Risk in Communities 
IRAS = Insulin Resistance Atherosclerosis Study 
PREDIMED = Prevencion con Dieta Mediterranea 
HYRIM = Hypertension High Risk Management trial 
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ELSA = The European Lacidipine Study on Atherosclerosis 
ORIGIN = Outcome Reduction with an Initial Glargine Intervention 
GRACE = Glucose Reduction and Atherosclerosis Continuing Evaluation Study 
EDIC = Epidemiology of Diabetes Interventions and Complications 
DCCT = Diabetes Control and Complications Trial 
RADIANCE = Rating Atherosclerotic Disease Change by Imaging with a New CETP 
Inhibitor 
IMPROVE = Carotid Intima Media Thickness [IMT] and IMT-Progression as Predictors of 
Vascular Events
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Supplemental table 1. Cigarette smoking.  
Study population (n) 
[Ref] Age, y* Male, % 
Follow-up, 
y 
(mean 
values) 
Carotid 
Segments** 
Carotid 
side 
Arterial 
interface 
measured 
Intervention 
type Results 
Plaques 
included in 
IMT 
Evidence of association between smoking habits and C-IMT progression 
Population based cohort 
(n=128) [10] 42, 48, 54 or 60***
 100 2 CC Right and Left Far wall NA 
Smoking was a significant predictor of C-
IMTp no 
MetS patients (n=301) 
[12] 68.3 69 1 CC 
Right 
and Left Far wall NA 
C-IMT regression was observed in never 
and past smokers and quitters (by -2.78%, 
-0.33%, and -1.16%, respectively), 
whereas persistent smokers showed a 
progression of 33.3% from baseline. 
no 
Population based cohort 
(n=3409) [4] 65.4 38 6.5 CC 
Right 
and Left 
Near and Far 
wall NA 
Smoking was a significant predictor of C-
IMTp no 
Population based cohort 
(n=3426) [7] 56.3 41 16 CC Right Far wall NA 
Smoking was positively associated with C-
IMTp yes 
Healthy subjects 
(n=364) [18] 48.5 100 2.3 CC Left Far wall NA 
Smoking was a significant predictor of C-
IMTp no 
Hypercholesterolemic 
patients (n=426) [20] 57 100 3 
CC 
Bulb 
Right 
and Left Far wall NA 
C-IMTp was higher in smokers compared to 
nonsmokers yes 
Population based cohort 
(n=1192) [14] 
53.7 (NGT) 
56.6 (IGT) 
56.6 (UD) 
56.7 (DD) 
44 5.2 CC ICA 
Right 
and Left 
Near and Far 
wall NA 
Smoking was positively associated with C-
IMTp yes 
Population based cohort 
(n=1207) [15] 
53.7 (NGT) 
56.6 (IGT) 
56.6 (UD) 
56.7 (DD) 
44 5.2 CC ICA 
Right 
and Left 
Near and Far 
wall NA 
Smoking was positively associated with C-
IMTp yes 
Population based cohort 
(n=10914) [11] 54 43 3 
CC 
Bulb 
ICA 
Right 
and Left Far wall NA 
Smoking was associated with a 50% increase 
in C-IMTp. Exposure to environmental 
tobacco smoke was associated with a 20% 
increase in C-IMTp. 
no 
Stroke- and myocardial 
infarction-free subjects 
(n=712) [8] 
54.7 38 4.3 
CC 
Bulb 
ICA 
Right 
and Left Far wall NA 
Smoking was a significant predictor of C-
IMTp no 
Population based cohort 
(n=842) [13] 36.4 42 2.4 
CC 
Bulb 
ICA 
Right 
and Left  Far wall NA 
Smoking was positively associated with C-
IMTp yes 
Population based cohort 
(n=3383) [16] 51.7 49 3 
CC 
Bulb 
Right 
and Left Far wall NA 
Smoking was a significant predictor of C-
IMTp yes 
30 
 
ICA 
Population based cohort 
(n=12644) [17] 45–64 (range) 45 9 
CC 
Bulb 
ICA 
Right 
and Left Far wall NA 
Smoking was positively associated with C-
IMTp yes 
Population based cohort 
(n=336) [19] 32.3 38 5.8 
CC 
Bulb 
ICA 
Right 
and Left Far wall NA 
Smoking was a significant predictor of C-
IMTp yes 
T1DM patients 
(n=1116) [21] 35 52 12 
CC 
Bulb 
ICA 
Right 
and Left Not available NA 
Smoking was a significant predictor of C-
IMTp  no 
CAD patients (n=141) 
controls (n=139) [22] 
61.6 (CAD patients) 
56.3 (controls) 49 3 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall NA 
Smoking was positively associated with C-
IMTp in CAD patients. yes 
Smoking cessation: evidence level of causality 
Current smokers 
(n=795) [24] 45.2 42 3 CC 
Right 
and Left Far wall 
smoking 
cessation 
pharmacotherapi
es (n=795) 
Smoking status was not a significant predictor 
of C-IMTp. no 
*mean value reported or otherwise indicated, **carotid segments where IMT was measured, ***age-stratified sample of men 42, 48, 54, or 60 years 
old, CC=common carotid, ICA=internal carotid artery, NA=not applicable, NGT=normal glucose tolerance, IGT=impaired glucose tolerance, 
UD=undiagnosed diabetes, DD=diagnosed diabetes, T1DM=type 1 diabetes mellitus, CAD=coronary artery disease.  
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Supplemental table 2. Alcohol consumption.  
Study population (n) 
[Ref] Age, y* Male, % 
Follow-up, 
y 
(mean 
values) 
Carotid 
Segments** 
Carotid 
side 
Arterial 
interface 
measured 
Intervention 
type Results 
Plaques 
included in 
IMT 
Evidence of association between alcohol consumption and C-IMT progression 
Population-based cohort 
(n=1022) [25] 42, 48, 54 or 60*** 100 4 CC 
Right 
and Left Far wall NA 
Alcohol consumption was positively 
associated with C-IMTp no 
Population-based cohort 
(n=751) [26] 42, 48, 54 or 60*** 100 11 CC 
Right 
and Left Far wall NA 
Alcohol consumption was positively 
associated with C-IMTp no 
*mean value reported or otherwise indicated, **carotid segments where IMT was measured, ***age-stratified sample of men 42, 48, 54, or 60 years 
old, CC=common carotid, NA= not applicable. 
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Supplemental table 3. Diet style.  
Study population (n) 
[Ref] Age, y* Male, % 
Follow-up, 
y 
(mean 
values) 
Carotid 
Segments** 
Carotid 
side 
Arterial 
interface 
measured 
Intervention 
type Results 
Plaques 
included in 
IMT 
Evidence of association between diet style and C-IMT progression 
Middle age subjects 
(n=500) [29] 40-60 (range)  54 3 CC 
Right 
and Left Far wall NA 
Viscous fiber intake and pectin intake were 
inversely associated with C-IMTp no 
Cohort of utility 
employees (n=480) 
[30,31]  
49.9 53 1.5 CC Right and Left Far wall NA 
Lutein, beta-cryptoxanthin, zeaxanthin and 
alpha-carotene levels were inversely 
associated with C-IMTp 
no 
Middle-aged subjects 
(n=840) [32] 55.6 100 6 CC 
Right 
and Left Far wall NA 
Lycopene, alpha-carotene and beta-carotene 
levels were inversely associated with C-IMTp no 
Healthy adults (n=2494) 
[33] 60.2 38 5.4 CC 
Right 
and Left Far wall NA 
Dietary sodium intake was positively 
associated with C-IMTp no 
Middle-aged subjects 
(n=840) [32] 55.6 100 6 CC 
Right 
and Left Far wall NA 
Lycopene, alpha-carotene and beta-carotene 
levels were inversely associated with C-IMTp no 
Middle-aged subjects 
(n=802) [27] 40–69 (range) 44 5 
CC 
ICA 
Right 
and Left Far wall NA 
Higher intakes of less healthful foods and 
lower intakes of more healthful foods were 
positively associated with C-IMTp 
yes 
Middle aged subjects 
(n=1178) [28] 55.2 44 5 
CC 
ICA 
Right 
and Left 
Near and Far 
wall NA 
Whole-grain intake was inversely associated 
with C-IMTp yes 
Dietary changes: evidence level of causality 
Elderly subjects 
(n=464) [34]  70 100 3 CC 
Not 
available Far wall 
diet (n=233) 
no diet (n=231) 
Dietary intervention slowed C-IMTp compared 
with controls (0.044±0.091 vs 0.062±0.105 
mm; P=0.047) 
no 
High-cardiovascular-risk 
asymptomatic subjects 
(n=187) [35] 
67 49 1 CC Right and Left Far wall 
MedDiet+virgin 
olive oil (n=66) 
MedDiet+nuts 
(n=59) 
control diet 
(n=62) 
No significant between-group differences in 
C-IMTp were observed. Among participants 
with baseline IMT≥0.9 mm, C-IMTp versus 
control showed significant differences of -
0.079 mm (-0.145 to -0.012) for the 
MedDiet+virgin olive oil and -0.072 mm (-
0.140 to -0.004) for the MedDiet+nuts 
no 
T2DM patients 
(n=118) [37] 
56 (diet) 
57 (controls) 56 1 CC 
Right 
and Left Far wall 
diet (n=58) 
controls (n=60) 
C-IMT regression was higher in the diet group 
compared with control group (-0.02±0.04 vs -
0.004±0.04 mm; p=0.009) 
no 
Postmenopausal women 
(n=325) [40] 
60.8 (isoflavone 
group) 
60.9 (placebo group) 
0 2.7 CC Right Far wall 
isoflavone soy 
protein (n=162) 
placebo (n=163) 
C-IMTp was similar in the soy protein and in 
the placebo group [0.0048 (0.0034-0.0062) vs 
0.0057 (0.0043-0.0071) mm/y, p=ns] 
no 
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T2DM patients 
(n=60) [38] 
59.0 (EPA group) 
61.2 (control group) 60 2.1 CC 
Right 
and Left Far wall 
EPA (n=30) 
controls (n=30)  
C-IMTp was slower in the EPA group 
compared with the control group 
(−0.029±0.112 mm vs 0.016±0.109 mm, 
p=0.029) 
no 
Hypertensive patients 
(n=56) [39] 64 48 1 CC Left Far wall 
three weekly 
meals of fish 
(n=56) 
Changes in the PUFA/SFA ratio were 
inversely associated with C-IMTp no 
Patients with prior 
coronary artery bypass 
graft surgery (n=146) [41] 
54.2 100 2 CC Right Near and Far wall 
high 
supplementary 
vitamin E users 
(n=22), low 
supplementary 
vitamin E users 
(n=124) 
C-IMTp was slower in high supplementary 
vitamin E users compared with low vitamin E 
users (0.008±0.023 mm/y vs 0.023±0.020 
mm/y, p=0.03) 
no 
Chronic smokers (n=331) 
[42] 63.5 43 4 CC Right Not available 
vitamin E (n=170) 
placebo (n=161) 
C-IMTp was similar between vitamin E and 
placebo [0.0035 (- 0.0008, 0.0078) mm/y vs –
0.0005 [-0.0049, 0.0039] mm/y, p=ns) 
no 
Subjects in primary 
prevention, >40 years old 
and with LDL >130 mg/dL 
(n=258) [43] 
56.2 48 3 CC Right Far wall 
vitamin E 
(n=121),  
placebo (n=137) 
C-IMTp was similar between vitamin E and 
placebo (0.0040±0.0007 vs 0.0023±0.0007 
mm/y, p=ns) 
no 
Hypercolesterolemic men 
and post-menopausal 
women (n=458) [45] 
45-69 (range) 49 3 CC Right and Left Far wall 
placebo (n=110) 
vitamin E (n=115)  
vitamin C (n=120) 
vitamin E and C 
(n=113) 
Only combination of vitamin E and C slowed 
C-IMTp compared with placebo (0.011 vs 
0.020 mm/y, p=0.008)  
no 
Hypercolesterolemic men 
and post-menopausal 
women (n=440) [46] 
45-69 (range) 49 6 CC Right and Left Far wall 
placebo (n=105) 
vitamin E and C 
(n=335) 
Combination of vitamin E and C slowed C-
IMTp compared with placebo (0.010 vs 0.014 
mm/y, p=0.034) 
no 
High-cardiovascular-risk 
asymptomatic subjects 
(n=164) [36] 
66 46 2.4 
CC 
Bulb 
ICA 
Right 
and Left Far wall 
MedDiet+virgin 
olive oil (n=57) 
MedDiet+nuts 
(n=46) 
control diet 
(n=61) 
IMT progressed in the control diet group 
[0.052 mm (−0.014 to 0.118)] regressed in the 
MedDiet+nuts group [−0.084 mm (−0.158 to 
−0.010)], remained stable in the 
MedDiet+extra virgin olive oil group [−0.003 
mm (−0.071 to 0.065)] 
no 
Subjects at high risk of 
CVD (n=693) [44] 
65.0 (Vitamin E) 
65.67 (placebo)  77 4.5 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
Vitamin E 
(n=349) 
placebo (n=344) 
C-IMTp was similar between vitamin E and 
placebo (0.0180±0.0022 vs 0.0174±0.0020, 
p=ns) 
yes 
*mean value reported or otherwise indicated, **carotid segments where IMT was measured, CC=common carotid, ICA=internal carotid artery, 
NA=not applicable, AFG=altered fetal growth, NFG=normal fetal growth, T2DM= type 2 diabetes mellitus, CVD=cardiovascular disease 
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Supplemental table 4. Physical activity.  
Study population (n) 
[Ref] Age, y* Male, % 
Follow-up, 
y 
(mean 
values) 
Carotid 
Segments** 
Carotid 
side 
Arterial 
interface 
measured 
Intervention 
type Results 
Plaques 
included in 
IMT 
Evidence of association between physical activity and C-IMT progression 
Middle aged subjects 
(n=500) [47] 50 54 3 CC 
Right 
and Left Far wall NA 
C-IMTp was the highest in sedentary subjects 
(0.143±0.017 mm/y), intermediate in 
moderately active subjects (0.102±0.001 
mm/y) and the lowest  in vigorously active 
subjects (0.055±0.015 mm/y) (p for trend 
<0.0001) 
no 
Population based cohort 
(n=612) [48] 49.5 100 11 CC 
Right 
and Left Far wall NA 
Occupational physical activity was positively 
associated with C-IMTp no 
Healthy subjects (n=495) 
[49] 
 
44 49 3 
CC 
Bulb 
ICA 
Right 
and Left Far wall NA 
C-IMTp was not associated to sedentary 
behaviour or to the average intensity of 
physical activity 
no 
Physical activity interventions: evidence level of causality 
T2DM patients (n=51) 
[50] 58.5 52.5 1 CC Right Far wall 
Controls (n=22) 
MCT (n = 16) 
HIIT (n = 13) 
Intervention induced C-IMT regression in both 
MCT group (from 0.738±0.158 to 
0.712±0.111 mm, p<0.05) and HIIT group 
(from 0.734±0.159 to 0.724±0.119 mm, 
p<0.05)  
no 
Adolescents (n=74) [51]  11.6 48 1 CC Right Far wall Sport (n=14) Controls (n=60) 
C-IMTp was similar between sport group and 
controls [−0.001 (−0.010 to 0.008) mm vs 
0.006 (−0.013 to 0.024) mm]; p=ns 
no 
*mean value reported or otherwise indicated, **carotid segments where IMT was measured, CC=common carotid, ICA=internal carotid artery, 
NA=not applicable, T2DM= type 2 diabetes mellitus, CAD=coronary artery disease, MCT=moderate continuous training, HIIT=high-intensity interval 
training 
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Supplemental table 5. Combined lifestyle modifications.  
Study population (n) 
[Ref] Age, y* Male, % 
Follow-up, 
y 
(mean 
values) 
Carotid 
Segments** 
Carotid 
side 
Arterial 
interface 
measured 
Intervention 
type Results 
Plaques 
included in 
IMT 
Combined dietary and physical activity interventions: evidence level of causality 
Hypercholesterolemic 
patients (n=1390) [53] 56.9 29 2 CC 
Right 
and Left Far wall 
lifestyle 
modification 
(n=437) 
lifestyle 
modification plus 
lipid-lowering 
drug (n=159) 
controls (n=794) 
Lifestyle modification induced C-IMT 
regression both alone (−4.8 % in women and 
-6.8% in men) or in association with lipid-
lowering drugs (-8% in women and -16.7% in 
men)  
 
 
no 
Obese children (33 
NAFLD and 46 non-
NAFLD) [54] 
17 100 1 CC Right and Left Far wall 
diet, exercise and 
psychological 
support (n=79) 
Intervention induced C-IMT regression in both 
NAFLD (from 0.41±0.06 to 0.37±0.08 mm, 
p<0.05) and non-NAFLD (from 0.41±0.06 to 
0.35±0.05 mm, p<0.05) obese adolescents 
no 
Obese adolescents 
(n=77)  
[55] 
16.7 38 1 CC Right and Left Far wall 
interdisciplinary 
intervention 
(n=77) 
Intervention induced C-IMT regression no 
Postmenopausal women 
(n=420) [56] 57 0 4 
CC 
Bulb 
Right 
and Left 
Near and Far 
wall 
lifestyle change 
(n=203), Health 
Education 
(n=217) 
C-IMTp was similar between Lifestyle Change 
and Health Education groups (0.067 vs 0.078 
mm, p=ns) 
yes 
Drug-treated hypertensive 
patients (n=568) [57] 
56.8 fluvastatin 
57.5 placebo  
57.9 fluvastatin and 
lifestyle modification  
56.4 placebo and 
lifestyle modification  
100 4 CC Bulb  Right Not available 
fluvastatin 
(n=142) placebo 
(n=143) 
fluvastatin and 
lifestyle 
modification 
(n=141) 
placebo and 
lifestyle 
modification 
(n=142) 
Lifestyle intervention had no effect on C-
IMTp. 
C-IMTp was 0.049±0.165 mm in the placebo 
and lifestyle modification group and 
0.076±0.101 mm in the placebo group (p=ns). 
C-IMTp was 0.065±0.097 mm in the 
fluvastatin and lifestyle modification group 
and 0.049±0.094 mm in the fluvastatin group 
(p=ns). 
yes 
Middle-aged subjects 
(n=354) [52] 49 0 4 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
lifestyle 
intervention 
(n=166) 
controls (n=188) 
In perimenopausal/postmenopausal women, 
lifestyle intervention slowed C-IMTp 
compared to controls (0.004 vs 0.008 mm/y, 
p=0.02) 
yes 
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*mean value reported or otherwise indicated, **carotid segments where IMT was measured, CC=common carotid, ICA=internal carotid artery, 
NAFLD=non-alcoholic fatty liver disease 
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Supplemental table 6. Obesity  
Study population (n) 
[Ref] Age, y* Male, % 
Follow-up, 
y 
(mean 
values) 
Carotid 
Segments** 
Carotid 
side 
Arterial 
interface 
measured 
Intervention 
type Results 
Plaques 
included in 
IMT 
Evidence of association between obesity and C-IMT progression 
Population based cohort 
(n=9316) [58]  55 44 9 CC 
Right 
and Left Far wall NA BMI was not a significant predictor of C-IMTp no 
Middle-aged subjects 
(n=573) [59]  
48.8 (men) 
51.5 (women) 54 3 CC 
Right 
and Left Far wall NA BMI was a significant predictor of C-IMTp no 
Current smokers (n=795) 
[24]  45.2 42 3 CC 
Right 
and Left Far wall NA BMI was a significant predictor of C-IMTp no 
Population based cohort 
(n=1809) [60] 32 44 6 CC Left Far wall NA 
Waist circumference was positively 
associated with C-IMTp no 
Population based cohort 
(n=774) [61] 42, 48, 54, 60*** 100 4 CC 
Right 
and Left Far wall NA 
Waist-to-hip ratio was positively associated 
with C-IMTp no 
CAD patients (n=141) 
controls (n=139) [22] 
61.6 (CAD patients) 
56.3 (controls) 49 3 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall NA 
Waist-to-hip ratio was positively associated 
with C-IMTp in CAD patients yes 
Weight loss in obesity: evidence level of causality 
Obese patients (n=54) 
[62] 
41.2 (success group) 
40.5 (failure group) 19 10 CC 
Right 
and Left Far wall 
nutritional 
treatment (n=54) 
IMT significantly increased in the failure group 
(10 year weight change >0.5 kg; 0.06±0.02 
mm; p=0.004) and significantly decreased in 
the success group (10 year weight change 
≤0.5 kg; −0.07±0.03 mm; p=0.027) 
no 
Overweight children 
(n=82) 
[63] 
10 66 1 CC Right and Left Far wall 
diet (n=41) 
diet and exercise 
(n=41) 
A regression of IMT was observed in both 
children on diet [-0.015 mm (-0.025 to -
0.006); p=0.02] and on diet/exercise [-0.018 
mm (-0.028 to -0.008); p<0.001] 
no 
Obese children with 
NAFLD (n=120) [64] 11.9 54 1 CC 
Right 
and Left Not available 
diet and exercise 
(n=120) 
IMT did not change significantly: from 0.54 
(0.52-0.57) to 0.53 (0.48-0.54) mm, p=ns no 
Obese women (n=58)[66] 48.5 0 1 CC Right and Left Far wall 
gastric bypass 
(n=20) 
sleeve 
gastrectomy  
(n=20) 
Controls (n=18) 
A regression of IMT was observed in both 
gastric bypass group (-0.11±0.1 mm; p<0.05) 
and sleeve gastrectomy group (-0.08±0.09 
mm; p<0.05) whereas no changes were 
observed in the control women who had 
conventional therapy (+0.01±0.11 mm; p<ns) 
no 
Obese patients (n=111) 
[67] 42.5 17 1 CC 
Right 
and Left 
Near and Far 
wall 
Bariatric surgery 
(n=111) 
A regression of IMT was observed in both 
women (from 0.619±0.11 to 0.587±0.10 mm; no 
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p=0.005) and men (from 0.675±0.10 to 
0.622±0.11 mm; p=0.0.37) 
Patients with abdominal 
obesity and MetS (n=661)  
[68] 
62.8 51 2.5 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
rimonabant 
(n=326) 
placebo (n=335) 
C-IMTp was similar in the rimonabant group 
(0.010±0.095 mm) and in the placebo group 
(0.012±0.091 mm) (p=ns) 
yes 
*mean value reported or otherwise indicated, **carotid segments where IMT was measured, ***age-stratified sample of men 42, 48, 54, or 60 years 
old, CC=common carotid, ICA=internal carotid artery, NA= not applicable, T1DM=type 1 diabetes mellitus, CAD=coronary artery disease, 
T2DM=type 2 diabetes mellitus, NAFLD=non-alcoholic fatty liver disease, MetS=metabolic syndrome. 
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Supplemental table 7. Metabolic syndrome.  
Study population (n) 
[Ref] Age, y* Male, % 
Follow-up, 
y 
(mean 
values) 
Carotid 
Segments** 
Carotid 
side 
Arterial 
interface 
measured 
Intervention 
type Results 
Plaques 
included in 
IMT 
Evidence of association between metabolic syndrome and C-IMT progression 
Population based cohort 
(n=1809) [60] 32 44 6 CC Left Far wall NA 
C-IMTp was 0.079±0.007 mm in subjects with 
MetS and 0.042±0.002 mm in subjects 
without MetS (p<0.0001) 
no 
Population based cohort  
(n=1673) [69] 
48.8 (men) 
 46.8 (women) 49 1.2 CC Right Far wall NA 
Presence of MetS was positively associated 
with C-IMTp. no 
Population based cohort 
(n=370) [71] 66 (median) 34 2.15 CC 
Right 
and Left Far wall NA 
Presence of MetS was positively associated 
with C-IMTp no 
Healthy subjects (n=293) 
[72] 36.6 47 6 CC Right Not available NA 
Presence of MetS was positively associated 
with C-IMTp no 
Middle-aged subjects 
(n=500) [75] 
48.7 (men) 
51.4 (women)  54 3 CC 
Right 
and Left Far wall NA 
Atherogenic effects of MetS were mediated 
through its components; triglycerides were 
significantly associated with C-IMTp in 
women only. SBP was significantly 
associated with C-IMTp in men and women. 
no 
Population based cohort 
(n=1673) [76] 31.5 49 6 CC Left Far wall NA 
The recovery group (MetS at baseline but not 
at follow up) had reduced C-IMTp compared 
with the persistent group (0.036±0.005 vs 
0.079±0.010 mm; p<0.001) 
no 
Middle-aged subjects 
(n=316) [70] 58 100 3.2 
CC 
Bulb 
Right 
and Left Far wall NA 
Presence of MetS was positively associated 
with C-IMTp yes 
Population based cohort 
(n=2974) [73] 
55.5 (men with 
MetS) 
56.2 (men without 
MetS) 
60.4 (women with 
MetS)  
56.0 (women without 
MetS) 
48 13 CC Bulb 
Right 
and Left 
Near and Far 
wall NA 
MetS was a significant predictor of C-IMTp 
only in subjects below 50 years of age, but 
not in other age groups 
no 
Hypertensive patients 
(n=1444)  [74] 56 55 4 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall NA 
Presence of MetS was not associated with C-
IMTp yes 
*mean value reported or otherwise indicated, **carotid segments where IMT was measured, CC=common carotid, ICA=internal carotid artery, 
NA=not applicable, MetS=metabolic syndrome. 
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Supplemental table 8. Glucose derangement.  
Study population (n) 
[Ref] Age, y* Male, % 
Follow-up, 
y 
(mean 
values) 
Carotid 
Segments** 
Carotid 
side 
Arterial 
interface 
measured 
Intervention 
type Results 
Plaques 
included in 
IMT 
Evidence of association between glucose derangement and C-IMT progression 
Population based cohort 
(n=3409) [4] 65.4 38 6.5 CC 
Right 
and Left 
Near and Far 
wall NA 
Diabetes was a significant predictor of C-
IMTp no 
Population based cohort 
(n=3534) [78] 69 41 2 CC 
Right 
and Left Far wall NA 
Diabetic subjects showed enhanced C-IMTp 
compared with nondiabetic subjects [0.018 
(0.016, 0.023) vs 0.011 (0.007, 0.015) mm/y, 
p=0.03] 
no 
T2DM patients (n=68) 
[79] 59.9 63 3.5 CC 
Right 
and Left 
Near and Far 
wall NA 
C-IMTp was higher in women than in men 
(0.018±0.027 vs 0.007±0.022 mm/y, p=0.021) no 
T2DM patients (n=287) 
[80] 
59.1 (men) 
58.5 (women) 45 4 CC 
Right 
and Left Far wall NA 
C-IMTp was higher in men than in women 
(0.030±0.025 vs 0.022±0.019 mm, p=0.0006) no 
Population based cohort 
(n=261) [81] 
56.7 (lowest IMT 
tertile) 
59.6 (middle IMT 
tertile) 
62.4 (highest IMT 
tertile) 
51 5 CC Right Far wall NA Fasting glucose was positively associated with C-IMTp no 
T2DM patients (n=152) 
[82] 63.5 39 2 CC 
Right 
and Left Far wall NA 
HbA1c and 2-h post-challenge glucose level 
were positively associated with C-IMTp no 
T2DM patients (n=218) 
[83] 62 (median) 56 2 CC 
Right 
and Left Far wall NA 
Glycemic indices HbA1c, glycated albumin 
(GA) and GA/A1c ratio were significantly 
associated with C-IMTp.  
no 
T2DM patients (n=499) 
[84] 
58 (HbA1c <7.5) 
54 (HbA1c >7.5) 34 3 CC 
Right 
and Left Far wall NA HbA1c was not a predictor of C-IMTp no 
Population based cohort 
(n=1536) [77] 49.8 40 3.5 
CC 
ICA 
Right 
and Left Far wall NA 
Diabetes was a significant predictor of C-
IMTp yes 
Population based cohort 
(n=1192) [14] 
53.7 (NGT) 
56.6 (IGT) 
56.6 (UD) 
56.7 (DD) 
44 5.2 CC ICA 
Right 
and Left 
Near and Far 
wall NA 
C-IMTp was the lowest in subjects with NGT 
(0.038±0.013 mm/y), intermediate in patients 
with IGT (0.042±0.018 mm/y), and the highest 
in patients with undiagnosed and diagnosed 
diabetes (0.075±0.0.026 mm/y and 
0.072±0.019 mm/y) 
yes 
Population based cohort 
(n=473) [9] 
46.3 (Japanese 
American) 45 (white 
American)  
100 5 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall NA 
Diabetes was associated with C-IMTp only in 
Japanese American yes 
Population based cohort 
(n=3383) [16] 51.7 49 3 
CC 
Bulb 
Right 
and Left Far wall NA 
Diabetes was positively associated with C-
IMTp yes 
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ICA 
Population based cohort 
(n=12644) [17] 45–64 (range) 45 9 
CC 
Bulb 
ICA 
Right 
and Left Far wall NA 
Diabetes was positively associated with C-
IMTp yes 
T2DM patients (n=287) 
[3] 61.7 43 3.1 
CC 
Bulb 
ICA 
Right 
and Left Far wall NA HbA1c was a significant predictor of C-IMTp. yes 
Population based cohort 
(n=842) [13] 36.4 42 2.4 
CC 
Bulb 
ICA 
Right 
and Left Far wall NA 
Fasting glucose was positively associated 
with C-IMTp yes 
Population based cohort 
(n=336) [19] 32.3 38 5.8 
CC 
Bulb 
ICA 
Right 
and Left Far wall NA 
Fasting glucose was a significant predictor of 
C-IMTp yes 
Diabetes control: evidence level of causality 
IGT patients (n=132) [85] 54.8 (acarbose) 55.6 (placebo) 53 3.9 CC 
Not 
available Far wall 
acarbose (n=66) 
placebo (n=66) 
Acarbose slowed C-IMTp compared with 
placebo (0.02±0.07 vs 0.05±0.06 mm, 
p=0.027) 
no 
T2DM patients (n=70) 
[87] 
61.3 (nateglinide) 
61.8 (controls) 53 1 CC 
Right 
and Left Far wall 
nateglinide 
(n=34) controls 
(n=36) 
Nateglinide reduced C-IMTp compared to 
controls (-0.017±0.054 vs 0.024±0.066 mm/y, 
p=0.0064) 
no 
T2DM patients (n=322) 
[88] 
64.4 (alogliptin) 
64.8 (controls) 58 2 CC 
Right 
and Left Far wall 
alogliptin (n=161) 
controls (n=161) 
Alogliptin reduced C-IMTp compared to 
controls (-0.026±0.009 vs 0.005±0.009 mm, 
p=0.022) 
no 
T2DM patients (n=274) 
[89] 
63.8 (sitagliptin) 
63.6 (controls) 59 2 CC 
Right 
and Left Far wall 
sitagliptin (n=137) 
controls (n=137) 
Sitagliptin reduced C-IMTp compared to 
controls (-0.029±0.013 vs 0.024±0.013 mm, 
p=0.005) 
no 
T2DM patients (n=175) 
[91] 
52 (repaglinide) 
51 (glibenclamide) 53 1 CC 
Right 
and Left Far wall 
repaglinide 
(n=88) 
glibenclamide 
(n=87) 
Repaglinide was more effective than 
glibenclamide on C-IMTp (-0.029±0.021 vs -
0.005± 0.01 mm, p=0.02) 
no 
Insulin treated  
T2DM patients (n=276) 
[92] 
52.4 (troglitazone) 
52.6 (placebo) 67 2 CC Right Far wall 
troglitazone 
(n=142) placebo 
(n=134) 
C-IMTp was similar between troglitazone and 
placebo (0.0030±0.021 vs 0.0066±0.021 
mm/y, p=ns) 
no 
IGT patients (n=382) [96] 54 (pioglitazone) 53 (placebo) 46 2.3 CC Right Far wall 
pioglitazone 
(n=188) placebo 
(n=194) 
Pioglitazone slowed C-IMTp compared with 
placebo [0.00476 (0.00239 to 0.00714 vs 
0.00969 (0.00724 to 0.01215) mm/y, 
p=0.001) 
no 
T2DM patients (n=361) 
[97] 60 64 1.4 CC 
Right 
and Left Far wall 
pioglitazone 
(n=175) 
glimepiride 
(n=186) 
Pioglitazone was more effective than 
glimepiride on C-IMTp (−0.001 vs +0.012 
mm, p=0.02) 
no 
Women with gestational 
diabetes (n=192) [99] 
34.8 (troglitazone) 
34.2 (placebo) 0 4 CC Right Far wall 
troglitazone 
(n=93) 
Troglitazone slowed C-IMTp compared with 
placebo (0.0065 vs 0.0094 mm/y, p=0.048) no 
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placebo (n=99) 
Women with prior 
gestational diabetes 
(n=61)  
[100] 
40 0 3 CC Right Far wall pioglitazone (n=61) 
Patients were enrolled from the previous 
study (see Xiang AH 15623809). Pioglitazone 
slowed C-IMTp in patients previously treated 
with placebo (0.0031 vs 0.0100 mm/y, 
p=0.006). C-IMTp remained stable in patients 
previously treated with troglitazone (0.0037 vs 
0.0060 mm/y; p=0.26). 
no 
T2DM patients (n=200) 
IR patients (n=355) [93] 
68 (rosiglitazone) 
67 (placebo) 46 1 
CC 
Bulb Right Far wall 
rosiglitazone 
(n=277) placebo 
(n=278) 
C-IMTp was similar between rosiglitazone 
and placebo (0.049±0.007 vs 0.060±0.007 
mm, p=ns) 
yes 
T1DM patients (n=1116)  
[21] 35 52 12 
CC 
ICA 
Right 
and Left Not available 
conventional 
treatment 
(n=553) 
intensive 
treatment 
(n=563) 
Intensive treatment was more effective than 
conventional treatment on C-IMTp 
(0.072±0.011 vs 0.086±0.010 mm, p=0.048) 
no 
T1DM patients (n=1229)  
[102] 35 52 6 
CC 
ICA 
Right 
and Left Not available 
conventional 
treatment 
(n=611) 
intensive 
treatment 
(n=618) 
Intensive treatment was more effective than 
conventional treatment on C-IMTp [0.032 
(0.010 to 0.055) vs 0.046 (0.023 to 0.068) 
mm; p=0.01] 
yes 
T1DM patients (n=1116)  
[21] 35 52 12 
CC 
ICA 
Right 
and Left Not available 
conventional 
treatment 
(n=553) 
intensive 
treatment 
(n=563) 
Intensive treatment was more effective than 
conventional treatment on C-IMTp 
(0.072±0.011 vs 0.086±0.010 mm, p=0.048) 
no 
T1DM patients (n=1229)  
[102] 35 52 6 
CC 
ICA 
Right 
and Left Not available 
conventional 
treatment 
(n=611) 
intensive 
treatment 
(n=618) 
Intensive treatment was more effective than 
conventional treatment on C-IMTp [0.032 
(0.010 to 0.055) vs 0.046 (0.023 to 0.068) 
mm; p=0.01] 
yes 
T2DM patients (n=101) 
[86] 
58.6 (voglibose) 
60.4 (controls) 55 3 
CC 
Bulb 
ICA 
Right 
and Left Far wall 
voglibose (n=51) 
controls (n=50) 
Addition of voglibose reduced C-IMTp 
compared to controls (-0.021±0.144 vs 
0.098±0.122 mm/y, p< 0.0001) 
yes 
T2DM patients (n=118) 
[90] 
60.3 (glibenclamide) 
60.8 (gliclazide) 
 62.8 (glibenclamide 
+ metformin) 
49 3 
CC 
Bulb 
ICA 
Right 
and Left Far wall 
glibenclamide 
(n=59) gliclazide 
(n=30) 
glibenclamide + 
metformin (n=29) 
Glibenclamide plus metformin and gliclazide 
were more effective than glibenclamide alone 
on C-IMTp (0.041±0.105, 0.044±0.106, 
0.114±0.131 mm/y respectively, p=0.029 and 
p=0.035 respectively) 
yes 
T2DM patients (n=57) 
[94] 
62.6 (rosiglitazone) 
66.1 (placebo) 79 1 
CC 
Bulb 
Right 
and Left Not available 
rosiglitazone 
(n=28) 
C-IMTp was similar between rosiglitazone 
and placebo (0.04 vs 0.05 mm, p=ns) yes 
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ICA placebo (n=29) 
IGT or IFG patients 
(n=1256) [95] 54 45 3.09 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
rosiglitazone 
(n=635) 
placebo (n=621) 
C-IMTp was similar between rosiglitazone 
and placebo (0.0063±0.0011 vs 
0.0090±0.0011 mm/y; p=ns) 
yes 
T2DM patients (n=186) 
[98] 
56.7 (pioglitazone) 
57.2 (controls) 63 2.5-4 
CC 
Bulb 
ICA 
Right 
and Left Far wall 
pioglitazone 
(n=89)  controls 
(n=97) 
Pioglitazone slowed C-IMTp compared to 
controls (from 1.060±0.2368 to 0.992±0.1921 
mm; p=0.0042 for pioglitazione; from 
1.021±0.2136 to 0.990±0.2158, p=ns for 
controls) 
yes 
Dysglycemic patients at 
high risk for CVD 
(n=1091) [101] 
63.0 (insulin 
glargine) 
63.2 (standard care) 
64 4.9 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
insulin glargine 
(n=533) 
standard care 
(n=558) 
C-IMTp was similar between insulin glargine 
and standard care 0.0234±0.0015 vs 
0.0264±0.0015 mm/y, p=ns) 
yes 
T1DM patients (n=1116)  
[21] 35 52 12 
CC 
ICA 
Right 
and Left Not available 
conventional 
treatment 
(n=553) 
intensive 
treatment 
(n=563) 
Intensive treatment was more effective than 
conventional treatment on C-IMTp 
(0.072±0.011 vs 0.086±0.010 mm, p=0.048) 
no 
T1DM patients (n=1229)  
[102] 35 52 6 
CC 
ICA 
Right 
and Left Not available 
conventional 
treatment 
(n=611) 
intensive 
treatment 
(n=618) 
Intensive treatment was more effective than 
conventional treatment on C-IMTp [0.032 
(0.010 to 0.055) vs 0.046 (0.023 to 0.068) 
mm; p=0.01] 
yes 
*mean value reported or otherwise indicated, **carotid segments where IMT was measured, CC=common carotid, ICA=internal carotid artery, 
NA=not applicable, NGT=normal glucose tolerance, IGT=impaired glucose tolerance, UD=undiagnosed diabetes, DD=diagnosed diabetes, T2DM= 
type 2 diabetes mellitus, RA=rheumatoid arthritis, T1DM= type 1 diabetes mellitus, MetS=metabolic syndrome, IR=insulin resistance, IFG=impaired 
fasting glucose, CVD=cardiovascular disease 
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Supplemental table 9. Hypertension.  
Study population (n) 
[Ref] Age, y* Male, % 
Follow-up, 
y 
(mean 
values) 
Carotid 
Segments** 
Carotid 
side 
Arterial 
interface 
measured 
Intervention 
type Results 
Plaques 
included in 
IMT 
Evidence of association between hypertension and C-IMT progression 
Population based cohort 
(n=3409) [4] 65.4 38 6.5 CC 
Right 
and Left 
Near and Far 
wall NA 
SBP and/or hypertension were strong, 
independent predictors of C-IMTp no 
Population based cohort 
(n=3426) [7] 56.3 59 16 CC Right Far wall NA 
Favourable changes in SBP during follow-up 
decreased C-IMTp yes 
Middle-aged subjects 
(n=500) [75] 
48.7 (men) 
51.4 (women) 54 3 CC 
Right 
and Left Far wall NA SBP was positively associated with C-IMTp no 
Population based cohort 
(n=3364) [103] 
65 (normal subjects) 
 74 (subjects with 
CKD) 
41 4 CC Right and Left Far wall NA SBP was positively associated with C-IMTp no 
Insulin treated T2DM 
patients (n=276) [104] 52.2 33 2 CC Right Far wall NA SBP was positively associated with C-IMTp no 
Population based cohort 
(n=1038) [105] 42, 48, 54 or 60*** 100 4 CC 
Right 
and Left Far wall NA SBP was a significant predictor of C-IMTp yes 
Population based cohort 
(n=261) [81] 
56.7 (lowest IMT 
tertile) 
59.6 (middle IMT 
tertile) 
62.4 (highest IMT 
tertile) 
51 5 CC Right Far wall NA SBP was not associated with C-IMTp no 
Population based cohort 
(n=1026) [108] 52.6 100 4 CC 
Right 
and Left Far wall NA 
Men with SBP <120, 120 to 126, 127 to 134, 
135 to 143, and >143 mmHg had, 
respectively, an increase in mean IMT of 
0.074, 0.090, 0.110, 0.136, and 0.158 mm per 
4 years (p<0.001). Pulse pressure was 
positively associated with C-IMTp 
no 
Population based cohort 
(n=957) [107] 
65.2 (men) 
 65.1 (women) 41 4 CC 
Right 
and Left Far wall NA 
Pulse pressure was positively associated with 
C-IMTp yes 
Hypertensive patients 
(n=100) [109] 56 61 1 
CC 
Bulb 
Right 
and Left 
Near and Far 
wall NA 
SBP change was a significant predictor of C-
IMTp yes 
Population based cohort 
(n=1192) [14] 
53.7 (NGT) 
56.6 (IGT) 
56.6 (UD) 
56.7 (DD) 
44 5.2 CC ICA 
Right 
and Left 
Near and Far 
wall NA 
Hypertension was a significant predictor of C-
IMTp yes 
Population based cohort 
(n=1207) [15] 
53.7 (NGT) 
56.6 (IGT) 44 5.2 
CC 
ICA 
Right 
and Left 
Near and Far 
wall NA 
Hypertension was positively associated with 
C-IMTp yes 
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56.6 (UD) 
56.7 (DD) 
Population based cohort 
(n=1536) [77] 49.8 40 3.5 
CC 
ICA 
Right 
and Left Far wall NA 
Mean blood pressure was a significant 
predictor of C-IMTp yes 
Hypertensive 
postmenopausal women 
(n=618) [110] 
55 0 1 CC ICA 
Right 
and Left 
Near and Far 
wall NA 
SBP reduction during follow up was a 
significant predictor of C-IMTp no 
Stroke- and myocardial 
infarction-free subjects 
(n=712) [8] 
54.7 38 4.3 
CC 
Bulb 
ICA 
Right 
and Left Far wall NA 
Hypertension was a significant predictor of C-
IMTp no 
Population based cohort 
(n=473) [9] 
46.3 (Japanese 
American) 
45 (white American) 
100 5 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall NA 
Hypertension was positively associated with 
C-IMTp only in white Americans yes 
Population based cohort 
(n=3383) [16] 51.7 49 3 
CC 
Bulb 
ICA 
Right 
and Left Far wall NA 
Hypertension was positively associated with 
C-IMTp yes 
Population based cohort 
(n=842) [13] 36.4 42 2.4 
CC 
Bulb 
ICA 
Right 
and Left Far wall NA 
Mean arterial pressure was positively 
associated with C-IMTp yes 
Population based cohort 
(n=336) [19] 32.3 38 5.8 
CC 
Bulb 
ICA 
Right 
and Left Far wall NA SBP was a significant predictor of C-IMTp yes 
Patients with FH (n=904) 
or mixed dyslipidemia 
(n=752) [106] 
50.4 (atorvastatin) 
51.8 
(atorvastatin/torcetra
pib) 
56 2 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall NA 
SBP was positively associated with C-IMTp in 
the atorvastatin/torcetrapib group yes 
Population based cohort 
(n=12644) [17] 45–64 (range) 45 9 
CC 
Bulb 
ICA 
Right 
and Left Far wall NA 
Pulse pressure was positively associated with 
C-IMTp yes 
Control of hypertension: evidence level of causality 
Population based cohort 
(n=3441) [111] 60.3 47 9.4 CC 
Right 
and Left Far wall NA 
Antihypertensive use (β=−2.06; p=0.0004) 
and time on antihypertensive medications 
(β=−0.29; p<0.0001) were associated with 
lower C-IMTp 
no 
Hypertensive patients 
(n=155) [116] 
62.3 (olmesartan) 
62.1 (atenolol) 61 2 CC 
Right 
and Left Far wall 
olmesartan 
(n=78) 
atenolol (n=77) 
Olmesartan and atenolol produced 
comparable significant regressions in C-IMT 
(−0.090±0.015 vs −0.082±0.014 mm, p=ns)  
no 
Post-stroke hypertensive 
patients (n=326) [112]  69.3 63 1 CC 
Right 
and Left Far wall 
Cilnidipine 
(n=326) 
Cilnidipine reduced C-IMTp in patients with 
thicker baseline C-IMT [-0.09 (-0.13 to -0.05) 
mm] compared to normal group [-0.01 (-0.03 
to 0.01 mm); p<0.001 
yes 
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Hypertensive patients 
(n=55) [118] 
48 (amlodipine) 
49 (lisinopril) 59 1 CC 
Right 
and Left Far wall 
amlodipine 
(n=28) 
lisinopril (n=27) 
Amlodipine was more effective than lisinopril 
on C-IMTp [-0.048 (-0.066 to -0.031) vs -
0.027 (-0.046 to -0.007) mm, p<0.05) 
no 
T2DM patients (n=98) 
[119] 
56.4 (enalapril) 
56.3 (controls) 62 2 CC 
Right 
and Left 
Near and Far 
wall 
enalapril (n=48) 
controls (n=50) 
Enalapril slowed C-IMTp compared with 
controls (0.02±0.02 vs 0.01±0.02 mm/y; 
p<0.05) 
no 
Hypertensive patients 
(n=242) [120] 55-80 52 4 CC Right Far wall 
nifedipine 
(n=115) 
amiloride/HCTZ 
(n=127) 
C-IMT progressed significantly on 
amiloride/HCTZ but not on nifedipine 
0.034±0.007 vs -0.004±0.009 mm, p=0.002) 
no 
Patients with vascular 
disease (n=617) [122] 
60 (ramipril) 
61 (placebo) 65 4 CC 
Right 
and Left Far wall 
ramipril (n=308) 
placebo (n=309) 
C-IMTp was similar between ramipril (from 
0.80 to 0.83 mm) and placebo (from 0.79 to 
0.81 mm) (p=ns) 
no 
Patients with increased 
albuminuria (n=642) [123] 51 65 4 CC Left Far wall 
fosinopril (n=319) 
placebo (n=323) 
C-IMTp was similar between fosinopril and 
placebo (0.031±0.008 vs 0.043±0.009 mm, 
p=ns) 
no 
T2DM patients (n=499) 
[124] 
55 (aggressive 
treatment)  
57 (standard 
treatment) 
34 3 CC Right and Left Far wall 
aggressive 
treatment for BP 
and LDL targets 
(n=252) 
 standard 
treatment 
(n=247) 
IMT regressed in the aggressive group (from 
0.808 to 0.796 mm) and progressed in the 
standard group (from 0.797 to 0.837 mm, 
p<0.001). 
no 
Hypertensive patients 
(n=1519) [114,115] 
55.9 (atenolol) 
56.1 (lacidipine) 55 4 
CC 
Bulb 
Right 
and Left Far wall 
atenolol (n=764) 
lacidipine (n=755) 
Lacidipine was more effective than atenolol 
on C-IMTp (0.0087±0.0015 vs 0.0145±0.0015 
mm/y, p=0.0073) 
yes 
Stroke- and myocardial 
infarction-free subjects 
(n=712) [8] 
54.7 38 4.3 
CC 
Bulb 
ICA 
Right 
and Left Far wall NA 
Antihypertensive medication were significant 
predictor of C-IMTp no 
Hypertensive 
patients (n=4148) [112]  52 59 6.2 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall NA 
IMT increased in both patients with tight [from 
1.50 (1.46–1.53) to 1.69 (1.65–1.73) mm; 
p<0.05] or usual SBP control (from 1.55 
(1.52–1.58) to 1.75 (1.72–1.78) mm; p<0.05], 
without differences between groups (p=ns)   
yes 
Hypertensive patients 
(n=377) [113] 54.1 52 3.7 
CC 
Bulb 
ICA 
Right 
and Left Far wall 
verapamil 
(n=244) 
 chlortalidone 
(n=254) 
Verapamil was more effective than 
chlorthalidone on C-IMTp (–0.082 vs –0.037 
mm/y, p<0.02). 
yes 
Subjects at high risk CVD 
(n=693) [44] 
65.2 ramipril 10 mg 
65.6 ramipril 2.5 mg 
65.6 placebo 
77 4.5 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
ramipril 10 mg 
(n=227) 
ramipril 2.5 mg 
(n=232) 
placebo (n=234) 
C-IMTp was 0.0217±0.0027, 0.0180±0.0026 
and 0.0137±0.0024 mm/y respectively for 
placebo, ramipril 2.5 mg and ramipril 10 mg 
(p=0.033) 
yes 
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IGT or IFG patients 
(n=1256) [95] 54 45 3.09 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
ramipril (n=637) 
placebo (n=619) 
C-IMTp was similar between ramipril and 
placebo (0.0083±0.0011 vs 0.0069±0.0011, 
p=ns) 
yes 
*mean value reported or otherwise indicated, **carotid segments where IMT was measured, ***age-stratified sample of men 42, 48, 54, or 60 years 
old, CC=common carotid, ICA=internal carotid artery, NA=not applicable, NGT=normal glucose tolerance, IGT=impaired glucose tolerance, 
UD=undiagnosed diabetes, DD=diagnosed diabetes, CKD=chronic kidney disease, T2DM=type 2 diabetes mellitus, FH= familial 
hypercholesterolemia, CVD=cardiovascular disease, MetS=metabolic syndrome, IFG=impaired fasting glucose  
 
  
48 
 
Supplemental table 10. Dyslipidemia.  
Study population (n) 
[Ref] Age, y* Male, % 
Follow-up, 
y 
(mean 
values) 
Carotid 
Segments** 
Carotid 
side 
Arterial 
interface 
measured 
Intervention 
type Results 
Plaques 
included in 
IMT 
Evidence of association between dyslipidemia and C-IMT progression 
Population based cohort 
(n=3409) [4] 65.4 38 6.5 CC 
Right 
and Left 
Near and Far 
wall NA 
SBP and/or hypertension were strong, 
independent predictors of C-IMTp no 
Population based cohort 
(n=3426) [7] 56.3 59 16 CC Right Far wall NA 
Favorable changes in LDL and HDL 
cholesterol during follow-up were associated 
with reduced C-IMTp 
yes 
Population based cohort 
(n=128) [10] 42, 48, 54 or 60*** 100 2 CC 
Right 
and Left Far wall NA 
LDL cholesterol was a significant predictor of 
C-IMTp no 
Population based cohort 
(n=1809) [60] 32 44 6 CC Left Far wall NA 
LDL cholesterol was positively associated 
with C-IMTp no 
Employees (n=220) [127] 50.9 100 5 CC Right and Left Far wall NA 
Total cholesterol was positively associated 
with C-IMTp no 
Population based cohort 
(n=128) [128] 42, 48, 54 or 60*** 100 2 CC 
Right 
and Left Far wall NA 
LDL cholesterol was a significant predictor of 
C-IMTp no 
Healthy subjects (n=364) 
[18] 48.5 100 2.3 CC Left Far wall NA 
LDL cholesterol was a significant predictor of 
C-IMTp no 
Postmenopausal women 
(n=199) [130] 
60.6 (estradiol) 
61.6 (placebo) 0 2 CC Right Far wall NA 
LDL cholesterol was positively associated 
with C-IMTp, HDL was inversely associated 
with C-IMTp 
no 
Healthy subjects (n=571)  
[131] 44.0 42 3 CC Right Far wall NA 
Total cholesterol was a significant predictor of 
C-IMTp no 
T2DM patients (n=152) 
[82] 63.5 39 2 CC 
Right 
and Left Far wall NA 
LDL cholesterol was positively associated 
with C-IMTp, HDL was inversely associated 
with C-IMTp 
no 
Middle-aged subjects at 
moderate risk for CAD 
(n=134) [132] 
45-75 (range) 55 1.5 CC Right and Left 
Near and Far 
wall NA 
Triglycerides levels and the ratios TC/HDL-C, 
TG/HDL-C and Apo B/HDL-C were significant 
predictor of C-IMTp 
no 
Population based cohort 
(n=3441) [111] 60.3 47 9.4 CC 
Right 
and Left Far wall NA 
HDL cholesterol was inversely associated 
with C-IMTp. Statin use at baseline was a 
significant predictor of C-IMTp. 
no 
Middle-aged subjects 
(n=500) [133] 40-60 (range) 54 3 CC 
Right 
and Left Far wall NA 
HDL cholesterol was inversely associated 
with C-IMTp no 
Hypertensive patients 
(n=112) [134] 59 49 2 CC 
Right 
and Left Far wall NA 
HDL cholesterol was a significant predictor of 
C-IMTp no 
Middle-aged subjects at 
moderate risk for CAD 
(n=110) [135] 
45-75 (range) 56 1.5 CC Right and Left Far wall NA 
HDL cholesterol, HDL-2, HDL-3, VLDL-C and 
VLDL1+2-C were significant predictors of C-
IMTp 
no 
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Population based cohort 
(n=2743) [125] 
55.8 (men) 
56.6 (women) 48 13 
CC 
Bulb 
Right 
and Left 
Near and Far 
wall NA 
Total cholesterol was positively associated 
with C-IMTp no 
Middle-aged subjects 
(n=313) [126] 58 100 3.2 
CC 
Bulb 
Right 
and Left Far wall NA 
Total cholesterol, LDL cholesterol, 
triglycerides, apoB levels were positively 
associated with C-IMTp. HDL cholesterol was 
inversely associated with C-IMTp 
yes 
Postmenopausal women 
(n=84) [129] 58.7 0 5 
CC 
Bulb Right Far wall NA 
LDL cholesterol was positively associated 
with C-IMTp yes 
Middle-aged subjects 
(n=305) [136] 58 100 8.8 
CC 
Bulb 
Right 
and Left Far wall NA 
ApoB/ApoA-I ratio was positively associated 
with C-IMTp yes 
Population based cohort 
(n=1207) [15] 
53.7 (NGT) 
56.6 (IGT) 
56.6 (UD) 
56.7 (DD) 
44 5.2 CC ICA 
Right 
and Left 
Near and Far 
wall NA 
LDL cholesterol was positively associated 
with C-IMTp yes 
Population based cohort 
(n=842) [13] 36.4 42 2.4 
CC 
Bulb 
ICA 
Right 
and Left Far wall NA 
HDL cholesterol was inversely associated 
with C-IMTp yes 
Population based cohort 
(n=12644) [17] 45–64 (range) 45 9 
CC 
Bulb 
ICA 
Right 
and Left Far wall NA 
HDL cholesterol was inversely associated 
with C-IMTp yes 
CAD patients (n=141) 
controls (n=139) [22] 
61.6 (CAD patients) 
56.3 (controls) 49 3 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall NA 
HDL cholesterol was inversely associated 
with C-IMTp yes 
Population based cohort 
(n=473) [9] 
46.3 (Japanese 
American) 
45 (White American)  
100 5 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall NA 
The ratio total cholesterol/HDL cholesterol 
was positively associated with C-IMTp only in 
Japanese Americans 
yes 
FH patients (n=287) [138] 48 (atorvastatin) 49 (simvastatin) 40 2 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall NA Lp(a) level was not associated with C-IMTp yes 
T2DM patients with Lp(a) 
≤30 mg/dl (n=60) or Lp(a) 
>30 mg/dl (n=86) [137] 
63 (Lp(a) ≤30 mg/dl) 
64 (Lp(a) >30 mg/dl) 64 4 NA 
Right 
and Left Not available NA 
 Lp(a) level was a significant predictor of C-
IMTp no 
Control of dyslipidemia: evidence level of causality 
Population based cohort 
(n=3441) [111] 60.3 47 9.4 CC 
Right 
and Left Far wall NA 
HDL cholesterol was inversely associated 
with C-IMTp. Statin use at baseline was a 
significant predictor of C-IMTp. 
no 
CAD patients (n=74) 
[142] 37-67 (range) 91 4 CC Right Far wall 
lovastatin (n=49) 
placebo (n=25) 
Lovastatin slowed C-IMTp compared with 
placebo 
(-0.028±0.003 vs 0.015±0.005 mm/y, 
p<0.001) 
no 
Hypercholesterolemic 
patients (n=161) [150] 
58 (atorvastatin) 
61 (pravastatin) 71 1 CC 
Right 
and Left Far wall 
atorvastatin 
(n=79) 
Atorvastatin was more effective than 
pravastatin on C-IMTp (-0.034±0.021 vs 
0.025±0.017 mm; p=0.03) 
no 
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pravastatin 
(n=82) 
Patients with C-IMT >1.1 
mm and LDL >100 mg/dl 
(n=303) [156] 
66.3 57 1 CC Right and Left Far wall 
‘moderate’ 
pitavastatin 
(n=152) 
‘intensive’ 
pitavastatin 
(n=151) 
Only ‘intensive’ pitavastatin reduced C-IMTp 
[-0.045 (-0.071 to -0.019) mm, p<0.001 vs 
baseline], whereas ‘moderate’ pitavastatin 
had no significant effect [-0.0055 (-0.038 to 
0.028) mm, p=ns vs baseline]  
no 
Hypercholesterolemic 
patients (n=146) [151] 67.0 53 1 CC 
Right 
and Left Not available 
atorvastatin 
(n=73) 
pitavastatin 
(n=73) 
Pitavastatin was more effective than 
atorvastatin on C-IMTp (from 0.902±0.196 to 
0.857±0.212 mm vs 0.884±0.166 vs 
0.875±0.180, p<0.05) 
no 
Patients with prior 
coronary artery bypass 
graft surgery (n=78) 
[158,159] 
54.2 100 4 CC Right Near and Far wall 
colestipol/niacin 
(n=39) 
placebo (n=39) 
Colestipol/niacin slowed C-IMTp compared 
with placebo (-0.05±0.08 vs 0.05±0.08 mm, 
p<0.001)  
no 
T2DM patients (n=427) 
[160] 
55 (aggressive 
treatment plus 
ezetimibe) 
57 (aggressive 
treatment no 
ezetimibe) 
57 (standard 
treatment) 
33 3 CC Right and Left Far wall 
aggressive 
treatment plus 
ezetimibe (n=69) 
aggressive 
treatment no 
ezetimibe 
(n=154) 
standard 
treatment 
(n=204) 
C-IMT regressed similarly in patients  with 
aggressive treatment, with or without 
ezetimibe [-0.025 (-0.05 to 0.003) vs -0.012 (-
0.03 to 0.008) mm, p=ns), but progressed in 
the standard treatment [0.039 (0.02 to 0.06) 
mm, intergroup p < 0.0001]  
no 
CAD or CAD equivalent 
patients (n=208) 
[161,162] 
65 80 1.2 CC Right and Left Far wall 
ezetimibe 
(n=111) 
niacin (n=97) 
Niacin showed superior efficacy to ezetimibe 
on C- IMTp (−0.0142±0.0041 vs 
−0.0007±0.0035 mm, p<0.01) 
no 
CAD or CAD equivalent 
patients (n=161) [163] 65 80 
1.2 (n=111) 
0.6 (n=50) CC 
Right 
and Left Far wall 
ezetimibe 
(n=161) 
There was an inverse relationship between 
LDL-C and C-IMTp: greater reductions in 
LDL-C were associated with greater C-IMTp 
no 
T2DM patients (n=499) 
[124] 
55 (aggressive 
treatment)  
57 (standard 
treatment) 
34 3 CC Right and Left Far wall 
aggressive 
treatment for BP 
and LDL targets 
(n=252) 
 standard 
treatment 
(n=247) 
IMT regressed in the aggressive group (from 
0.808 to 0.796 mm) and progressed in the 
standard group (from 0.797 to 0.837 mm, 
p<0.001). 
no 
Population based cohort 
(n=2974) [139] 
55.8 (men) 
56.6 (women) 48 13 
CC 
Bulb 
Right 
and Left 
Near and Far 
wall NA 
Long-term use of lipid lowering drugs was a 
significant predictor of C-IMTp no 
Hypercholesterolemic 
patients (n=426) [20,145] 57 100 3 
CC 
Bulb 
Right 
and Left Far wall 
pravastatin 
(n=214) 
placebo (n=212) 
Pravastatin slowed C-IMTp compared with 
placebo (0.017 vs 0.031 mm/y, p=0.005) yes 
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Hypertensive patients 
(n=568) [57] 
56.8 (fluvastatin) 
57.5 (placebo) 
57.9 (fluvastatin and 
lifestyle 
modification) 
56.4 (placebo and 
lifestyle 
modification) 
100 4 CC Bulb Right Not available 
fluvastatin alone 
(n=142) placebo 
alone (n=143) 
fluvastatin and 
lifestyle 
modification 
(n=141) 
placebo and 
lifestyle 
modification 
(n=142) 
Fluvastatin slowed C-IMTp compared with 
placebo [mean difference -0.074 (-0.146 to -
0.012) mm, p=0.0214) 
yes 
Asymptomatic subjects 
with early carotid 
atherosclerosis (n=919) 
[140,141] 
61.7 52 3 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
lovastatin/placeb
o (n=231) 
warfarin/placebo 
(n=229)  
lovastatin/warfari
n (n=229) 
placebo/placebo 
(n=230) 
Lovastatin slowed C-IMTp compared with 
placebo 
(-0.009± 0.003 vs 0.006±0.003 mm/y; 
p=0.001) 
yes 
Asymptomatic subjects 
with early carotid 
atherosclerosis (n=919) 
[143] 
61.7 52 3 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
lovastatin/placeb
o (n=231) 
warfarin/placebo 
(n=229)  
lovastatin/warfari
n (n=229) 
placebo/placebo 
(n=230 
Women experienced the greatest C-IMT 
regression with lovastatin/warfarin 
combination (-0.0104±0.0052 mm/y), men 
with lovastatin alone (-0.0151±0.0048 mm/y) 
yes 
CAD patients (n=151)  
[144] 63 85 3 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
pravastatin 
(n=75) 
placebo (n=76) 
Pravastatin slowed C-IMTp compared with 
placebo in the common carotid 
(0.0295±0.0058 vs 0.0456±0.0057, p=0.03) 
yes 
Hypercholesterolemic 
patients (n=305) [146] 55 53 3 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
pravastatin 
(n=151) 
placebo (n=154) 
Pravastatin slowed C-IMTp compared with 
placebo 
(-0.0043±0.0028 vs 0.0089±0.0027 mm/y, 
p<0.0007) 
yes 
Low risk subjects (n=876) 
[147-149] 57.6 60 2 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
rosuvastatin 
(n=624) 
placebo (n=252) 
Rosuvastatin slowed C-IMTp compared with 
placebo [-0.0014 (−0.0041 to 0.0014) vs 
0.0131 (0.0087 to 0.0174) mm/y, p<0.001] 
yes 
T2DM patients (n=182) 
[152] 
58.8 (cerivastatin) 
58.2 (placebo) 47 2 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
Cerivastatin# 
(n=103) 
placebo (n=79) 
C-IMTp was similar between statin and 
placebo [0.002 (-0.0112 to 0.0149) vs -0.006 
(-0.0223 to 0.0109), p=ns] 
no 
Hypercholesterolemic 
patients (n=269) [157] 55 53 3 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
pravastatin 
(n=136) 
placebo (n=133) 
While in the placebo group a positive rate of 
C-IMTp was observed, in pravastatin group 
no IMT progression was recorded. C-IMTp 
did not correlate with the extent of LDL-C 
lowering. 
yes 
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FH patients (n=139) [164] 46.2 55 2 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
simvastatin 
(n=139) 
Simvastatin decreased C-IMTp from 0.92 
(0.91-0.94) to 0.87 (0.85-0.89) mm (p<0.001) no 
FH patients (n=280) [165] 48 39 2 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
atorvastatin 
(n=141) 
simvastatin 
(n=139) 
Atorvastatin showed superior efficacy to 
simvastatin on C-IMTp [-0.031 (-0.007 to -
0·055) vs 0.036 (0.014 to 0.058); p=0.0001] 
yes 
FH patients (n=255) [166] 48 39 2 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
atorvastatin 
(n=255) 
In the previous 2 
y, 123 were 
taking simvastatin 
and 132 
atorvastatin 
A complete arrest of C-IMTp (from 0.89 to 
0.90 mm, p=ns) was observed in patients 
previously taking atorvastatin. A significant 
regression (from 0.95 to 0.92 mm, p=0.01) 
was observed in patients previously taking 
simvastatin. 
yes 
FH patients (n=642) [168] 
45.7 (simvastatin) 
46.1 
(simvastatin/ezetimi
be) 
49 2 
CC 
Bulb 
ICA 
Right 
and Left Far wall 
simvastatin 
(n=320) 
simvastatin/ezeti
mibe (n=322) 
C-IMTp was similar between 
simvastatin/ezetimibe and simvastatin alone 
(0.0111±0.0038 vs 0.0058±0.0037 mm, p=ns) 
yes 
FH children (n=211) [169] 13.0 47 2 
CC 
Bulb 
ICA 
Right 
and Left Far wall 
pravastatin 
(n=104) 
placebo (n=107) 
Pravastatin slowed C-IMTp compared with 
placebo 
(-0.010±0.048 vs 0.005±0.044, p=0.02) 
yes 
FH patients (n=850) [170] 
45.2 (atorvastatin) 
46.8 
(atorvastatin/torcetra
pib) 
49 2 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
atorvastatin 
(n=427) 
atorvastatin/torcet
rapib (n=423) 
C-IMTp was similar between 
atorvastatin/torcetrapib and atorvastatin alone 
(0.0047±0.0028 vs 0.0053±0.0028 mm/y, 
p=ns) 
yes 
Mixed dyslipidaemia 
patients (n=683) [171] 
56.5 (atorvastatin) 
57.9 
(atorvastatin/torcetra
pib) 
64 2 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
atorvastatin 
(n=344) 
atorvastatin/torcet
rapib (n=339) 
C-IMTp was similar between 
atorvastatin/torcetrapib and atorvastatin alone 
(0.025±0.005 vs 0.030±0.005 mm/y, p=ns) 
yes 
FH (n=904) or mixed 
dyslipidaemia patients 
(n=752) [106] 
50.4 (atorvastatin) 
51.8 
(atorvastatin/torcetra
pib) 
56 2 
CC 
Bulb 
ICA 
Right 
and Left 
Near and Far 
wall 
atorvastatin 
(n=829) 
atorvastatin/torcet
rapib (n=827) 
C-IMTp was higher with 
atorvastatin/torcetrapib than with atorvastatin 
alone (0.0076±0.0011 vs 0.0025±0.0011 
mm/y; p=0.0014) 
yes 
*mean value reported or otherwise indicated, **carotid segments where IMT was measured, ***age-stratified sample of men 42, 48, 54, or 60 years, 
CC=common carotid, ICA=internal carotid artery, NA=not applicable, NGT=normal glucose tolerance, IGT=impaired glucose tolerance, 
UD=undiagnosed diabetes, DD=diagnosed diabetes, T2DM= type 2 diabetes mellitus, CAD=coronary artery disease, FH=familial 
hypercholesterolemia, MI= myocardial infarction, #when cerivastatin was withdrawn from the market, 0.4 mg cerivastatin was replaced by 20 mg 
simvastatin
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